



ASCP

AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY

2022 ANNUAL MEETING

Reassessing Research and Clinical
Practice in the Peri-pandemic Era

May 31-
June 03 | 2022



Fairmont Scottsdale Princess
Scottsdale, AZ



ASCP
AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY



Dear Colleagues,

Welcome to Scottsdale and sunshine!

On behalf of the American Society of Clinical Psychopharmacology (ASCP), I am pleased to welcome you to our very exciting, and much anticipated, annual meeting. I am thrilled to be back in-person and want to thank both the Program Committee and the Steering Committee for their wonderful work putting together an extraordinary hybrid meeting.

As we begin to enter this post-Covid era, we all are learning and navigating new approaches in our professional and personal lives. Thus, the 2022 ASCP Annual Meeting theme of "Reassessing Research and Clinical Practice in the Peri-pandemic Era" is quite timely and relevant for both our in-person attendees and those participating remotely. The ASCP Annual Meeting has something for everyone. There are sessions that discuss digital measurement and therapeutics, racial and ethnic disparities, ketamine therapies, as well evaluating and integrating new and novel treatments, including psychedelics. Our meeting also includes a very stimulating joint workshop with the American Foundation for Suicide Prevention (AFSP) and we also continue our long-standing and highly successful New Investigators' Program.

Additionally, we are resuming our in-person mealtime special events. The Early Career Breakfast will address "How to Initiate Productive Collaborations with Industry, as well as Nonprofit Organizations While Appropriately Balancing Conflicts" which promises to be a lively and interactive activity. The Inclusivity Committee will host a special luncheon entitled, "Snakes and Ladders in Academic Progression for Underrepresented Faculty" which will focus on career successes and challenges for individuals from underrepresented backgrounds. In addition, we have added early career tables to each lunch session - attendees of all career stages are welcome to sit and network!

Unique to the ASCP Annual Meeting is the active participation from colleagues in government service. We have renamed the Federal Agency Updates Plenary to Update from Federal and Other Funding Agencies and will include representatives from NIMH, NIAAA, PCORI, NIDA, SAMSHA, and the Department of Veterans Affairs. There is, of course, the very important and unique Regulatory Session that traditionally serves as the closing session of our meeting.

The ASCP Annual Meeting checks off all the boxes in our organization's strategic plan:

- Goal #1 – Enhance the development of cutting-edge research in the field of clinical psychopharmacology and related fields by providing investigators and clinicians the opportunity to engage in discussion, education, and dissemination of research findings and new methodologies
- Goal #2 - Enhance ASCP's role as the preeminent leader in innovative education in clinical psychopharmacology and related fields to foster the development of best practices, new treatments, curricula, and training for all career levels
- Goal #3 - Increase the leadership, membership, and participation of all underrepresented groups in the Society by cultivating inclusion to ensure that all feel welcomed, empowered, and valued
- Goal #4 - Create opportunities for individuals from diverse backgrounds, such as early career members and NIA's, to stay engaged in the Society

ASCP continues to aspire to become an exemplary leader in creating an inclusive and welcoming environment wherein everyone can learn, develop, innovate, and flourish.

I hope you have a wonderful time learning, presenting, and seeing old and new friends at our annual meeting.

Leslie Citrome, M.D., M.P.H.

President

American Society of Clinical Psychopharmacology

Welcome to the ASCP Annual Meeting

On behalf of the ASCP Annual Meeting Steering and Program Committees, we are delighted to welcome you to the ASCP Annual Meeting. The ASCP is committed to continue building on the past success of NCDEU with program innovation while preserving the rich history of this meeting. Below are some of the highlights of the 2022 meeting.

The annual meeting brings together academic investigators, industry scientists, U.S. and international regulators, National Institutes of Health (NIH) and other professionals who work in drug development and clinical trials.

2022 Program Highlights

- **Tuesday, May 31st:**
 - Conference Opening
 - Inclusivity Luncheon (RSVP Only)
 - Pharmaceutical Pipeline
 - Individual Research Reports
- **Wednesday, June 1st:**
 - 23rd Annual Fun Run/Walk
 - Early Career Breakfast (RSVP Only)
 - Regulatory Plenary
 - ASCP Lifetime Awardee Talk: *Looking Back, Giving Thanks, and Moving Forward: Reflections on 50 Years as Physician/Scientist/Mentor in Geriatric Psychiatry*
 - Poster Session I
 - ASCP Reception
- **Thursday, June 2nd:**
 - Keynote Plenary: *Reassessing Research and Clinical Practice in the Peri-pandemic Era*
 - Update From Federal and Other Funding Agencies Plenary
 - Poster Session II
 - Clinical Updates in Psychopharmacology
- **Friday, June 3rd:**
 - Regulatory Wrap-Up Plenary with FDA & EMA regulators
- **The New Investigator Program**
 - A closed workshop for 20 New Investigators and informal breakfast sessions
- **Workshops:** 2-hour intensive interactive sessions focused on problems and solutions
 - Wednesday Afternoon
- ***Clinical Track*** – Sessions focused on topics of immediate clinical relevance
- **+Not Accredited** – Per the new ACCME guidelines, these sessions cannot be accredited

Organization

- The meeting is sponsored by the American Society of Clinical Psychopharmacology (ASCP).
 - The Steering Committee organizes the meeting.
 - The Program Committee evaluates submitted proposals and develops program innovations.
- Update From Federal and Other Funding Agencies collaborations:
 - NIAAA – National Institute on Alcohol Abuse and Alcoholism
 - NIDA – National Institute of Drug Abuse
 - NIMH – National Institute of Mental Health
 - PCORI – Patient-Centered Outcomes Research Institute
 - SAMHSA – Substance Abuse and Mental Health Services Administration
 - VA – Veterans Administration
- Regulatory agency collaborations:
 - Food and Drug Administration (FDA)
 - European Medicines Agency (EMA)
 - The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM)
- Society collaboration:
 - American Foundation for Suicide Prevention (AFSP)
- Parthenon Management Group organizes the ASCP Annual Meeting.

And Remember

- The Fun Run/Walk is Wednesday, June 1st at 6:30 a.m. All are welcome to join!
- The ASCP Reception is Wednesday, June 1st from 6:00 p.m. – 7:00 p.m.

The ASCP Annual Meeting is an opportunity for education and networking. We welcome your suggestions to make the event even better. Seek us out during the meeting or provide your views by completing the evaluation form.

Best Regards,



Susan G. Kornstein, M.D.
Steering Committee Co-chair



Mark Rapaport, M.D.
Steering Committee Co-chair




Erika Saunders, M.D.
Program Committee Co-chair



Lee Cohen, M.D.
Program Committee Co-chair

Fairmont Scottsdale Princess



Award Winners and Featured Speakers	5
Acknowledgements	21
Meeting Announcements.....	27
Monday, May 30, 2022	31
Tuesday, May 31, 2022	35
Wednesday, June 1, 2022	49
Thursday, June 2, 2022	59
Friday, June 3, 2022	69
Pre-Recorded Sessions.....	74
Posters.....	75
Author Index	97

**DISCLOSURES FOR ALL ASCP PRESENTERS
CAN BE VIEWED AT WWW.ASCPMEETING.ORG**

[illegible]

Recipient of the Donald Klein Lifetime Achievement Award

Charles F. Reynolds III, M.D.
University of Pittsburgh School of Medicine

Charles F. Reynolds III, M.D. is Distinguished Professor of Psychiatry, UPMC Endowed Professor in Geriatric Psychiatry (emeritus) at the University of Pittsburgh School of Medicine, and Editor-in-Chief of the American Journal of Geriatric Psychiatry (AJGP).

Reynolds' research interests focus on mood, grief, and sleep disorders of later life, addressing mental health services in primary care, improving strategies for the care of treatment-resistant depression in later life, depression prevention, and promotion of brain health and cognitive fitness in later life. He was the 2016 co-recipient (with Vikram Patel) of the Pardes Humanitarian Prize in Mental Health, awarded by the Brain & Behavior Research Foundation for his "transformative work in geriatric psychiatry and the prevention and treatment of late-life depression."

In addition to his duties as Editor-in-Chief of the AJGP, Reynolds serves on the editorial board of JAMA Psychiatry. He and his team have published research in the New England Journal of Medicine, JAMA, the Lancet, the British Medical Journal, the American Journal of Psychiatry, and JAMA Psychiatry. Reynolds has mentored approximately 25 NIH K awardees. He is past recipient of an NIMH Research Scientist Award (K05; 1990-2000) and MERIT Award (R37; 1989-1999) for randomized clinical trials of maintenance pharmacotherapy and psychotherapy in late-life depression.

Reynolds graduated magna cum laude from U.Va. (1969, majoring in epistemology, moral philosophy, and theology [Paul Tillich and Victor Frankl] and from Yale Medical School (1973). He completed a straight medical internship at McGill (Royal Victoria Hospital and Montreal Neurological Hospital; 1973-1974) and psychiatry residency at Pittsburgh (1974-1977). He served on the Pitt Faculty of Medicine from 1977 to 2017 and now lives with his spouse of 50 years, Ellen Detlefsen, on the coast of Maine (where he is pretending to be "retired").

Recipient of the Paul Wender Best Paper in *The Journal of Clinical Psychiatry* Award



Brandon Nichter, Ph.D.
U.S. Special Operations Command

Nominated for: *Prevalence, Correlates, and Treatment of Suicidal Behavior in US Military Veterans: Results From the 2019-2020 National Health and Resilience in Veterans Study*

Dr. Brandon Nichter is a visiting research scientist at Yale School of Medicine, Department of Psychiatry, and a licensed clinical psychologist with the U.S. Air Force Special Operations Command. He earned his PhD in clinical psychology from Arizona State University, and completed his postdoctoral training at VA San Diego Healthcare System. Dr. Nichter's primary research interests include the epidemiology of psychiatric disorders in military populations; risk and protective factors for suicidal behavior; and the impacts of military-related moral injury.

2022 ASCP Nina Schooler Early Career Research Awardee



Nithya Ramakrishnan, M.S.
Baylor College of Medicine, The Menninger Clinic

Nominated for: *Neurophysiological and Clinical Effects of the NMDA Receptor Antagonist Lanicemine (BHV-5500) in PTSD: a Randomized, Double-blind, Placebo-controlled Trial*

Nithya Ramakrishnan, M.S. is a senior scientific programmer at Baylor College of Medicine, Department of Psychiatry and Behavioral sciences. She has a background in biomedical engineering and neuroscience. At Baylor, she plays lead roles in developing and conducting neuromodulation, and wearable device research projects and optimizes data analytical pipelines. Her area of expertise focuses on the development of signal processing techniques on electrophysiological data such as EEG and MEG to identify biomarkers of disease and treatment efficacy as well as in the context of concurrent brain stimulation such as deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS).



New Investigator Awardees

Aderonke Bamgbose Pederson, M.D.

Harvard Medical School

Camila Nayane de Carvalho Lima, Ph.D.

The University of Texas Health Science Center at Houston

Moein Foroughi, M.D.

SUNY Downstate Medical Center

Andrew Fukuda, M.D., Ph.D.

Brown University/Butler Hospital

Manuel Gardea Resendez, M.D.

Mayo Clinic

Evan Goldstein, Ph.D.

University of Utah

Eric Goldwaser, D.O., Ph.D.

University of Maryland/Sheppard Pratt

Alexander Herman, M.D., Ph.D.

The University of Minnesota

Jenessa Johnston, B.A.

University of Victoria

Benson Ku, M.D.

Emory University School of Medicine

Rakesh Kumar, M.D.

Mayo Clinic

Katharine Liang, M.D., Ph.D.

VA Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System

Nicholas Murphy, Ph.D.

Baylor College of Medicine

Jennifer Nicoloro, Ph.D.

Brigham and Women's Hospital, Harvard Medical School

Zhenhao Shi, Ph.D.

University of Pennsylvania

Norman Spivak, B.S.

David Geffen School of Medicine at UCLA

Amanda Tamman, M.Sc.

Baylor College of Medicine

Thanh Thuy Truong, M.D.

Baylor College of Medicine

Andrew Tubbs, Ph.D.

University of Arizona College of Medicine

Kevin Xu, M.D., M.P.H.

Washington University in St. Louis

Regulatory Plenary**Wednesday, June 1st: 8:30 a.m. – 10:00 a.m.**

Maria Tome, M.A.Sc., M.D., Ph.D., FFPM
European Medicines Agency

Professor Maria B. Tome Isaac is a Neuropsychiatrist training in US, Basque Country, UK and Dutch system. She is responsible for over 1100 drugs in development phase 1, 2 and 3. The European Medicines Agency is responsible for the licenses and safety of all the medicines for 450 million

EU citizens all with health insurance and all 450 million EU citizens have access to medication.



Tiffany Farchione, M.D.
US Food and Drug Administration

Dr. Farchione received her medical degree from Wayne State University in Detroit, Michigan, and completed adult residency and child & adolescent fellowship training at the University of Pittsburgh's Western Psychiatric Institute and Clinic. Dr. Farchione is board certified in both general and child & adolescent psychiatry. Prior to joining FDA in 2010, Dr. Farchione was affiliated with the University of Pittsburgh Medical Center, and was on the faculty of the


University of Pittsburgh.

As the Director of the Division of Psychiatry in the Office of Neuroscience at FDA, Dr. Farchione is involved in the oversight of new drug review for all psychiatric drug development activities conducted under INDs, and the review of all NDAs and supplements for new psychiatric drug claims.



Dominic Chiapperino, Ph.D.
US Food and Drug Administration

Dr. Chiapperino is currently the Director of the Controlled Substance Staff (CSS), in the Center for Drug Evaluation and Research, Office of the Center Director. In this position, he works extensively on FDA policy and regulatory issues related to drug abuse potential assessment and the evaluation of dependence liability. This work includes the assessment of new molecular entities, consideration of substances for drug scheduling under the Controlled Substances Act, and regulatory issues related to cannabis and the conduct of research with cannabis and its constituent compounds, including for purposes of drug development. Dr. Chiapperino received his PhD in organic chemistry from the University of Maryland in 2000 and conducted post-doctoral research with the National Institute of Diabetes and Digestive and Kidney Diseases before beginning his career with FDA in 2002.



Cynthia LaCivita, Pharm.D.
US Food and Drug Administration

Cynthia LaCivita earned her undergraduate degree in microbiology and a Doctor of Pharmacy from the University of Maryland. She completed a pharmacy oncology residency at the University of Maryland Cancer Center (UMCC). She had previously worked in genetic toxicology with Linton Bionetics. Cynthia was an assistant professor in the Department of Pharmacy Practice and Science at the U of Maryland School of Pharmacy and assistant professor of Oncology at UMCC, Director of Clinical Standards and Quality for the American Society of Health-System Pharmacists (ASHP) and Director of Education and Special Programs for the ASHP Research and Education Foundation. In April 2010 she joined the Food and Drug Administration and has served as the director of the Division of Risk Management (DRISK) since 2015.



Georgios Aislaitner, Ph.D.
European Medicines Agency

- January 2017- Present: Clinical Assessor and Lead Clinical Assessor in the Department of Neurology, Psychiatry and Ophthalmology, Federal Institute for Drugs and Medical Devices (BfArM) (Germany)
- March 2014-December 2016: Acting Director of Division of Validation of Applications and Issue of Marketing Authorisations, National Organisation for Medicines (EOF) (Greece)
- April 2014-December 2016: CHMP alternate for the National Organisation for Medicines (EOF) (Greece)
- July 2016-December 2016: Head of Electronic Data Management Section, National Organisation for Medicines (EOF) (Greece)
- December 2014-July 2016: Head of Validation and Registration of Applications Section, National Organisation for Medicines (EOF) (Greece)
- January 2012-March 2014: Head of Adverse Reactions Department, National Organisation for Medicines (EOF) (Greece)
- July 2012-April 2014: PRAC member for the National Organisation for Medicines (EOF) (Greece)
- April 2011-January 2012: Head of Section for the Evaluation of Medicinal Products, National Organisation for Medicines (EOF) (Greece)
- March 2008 -March 2012: CHMP member for the National Organisation for Medicines (EOF) (Greece)

Keynote Plenary: Reassessing Research and Clinical Practice in the Peri-pandemic Era

Thursday, June 2nd: 8:15 a.m. - 9:45 a.m.



Roy Perlis, M.D.
Massachusetts General Hospital

Roy Perlis, MD, MSc is Associate Chief for Research in the Department of Psychiatry, Director of the Center for Quantitative Health at Massachusetts General Hospital, and Ronald I. Dozoretz, MD Endowed Professor of Psychiatry at Harvard Medical School. He serves as Associate Editor for Neuroscience at JAMA's new open-access journal, JAMA Network - Open. He graduated from Brown University, Harvard Medical School and Harvard School of Public Health, and completed his residency, chief residency, and clinical/research fellowship at MGH before joining the faculty.

Dr. Perlis's research is focused on identifying predictors of treatment response in brain diseases, and using these biomarkers to develop novel treatments. He directs two complementary laboratory efforts, one focused on patient-derived cellular models and one applying machine learning to large clinical and databases.

Dr. Perlis has authored more than 350 articles reporting original research, in journals including JAMA, NEJM, Nature Genetics, Nature Neuroscience, the British Medical Journal, and the American Journal of Psychiatry. His research has been supported by awards from NIMH, NHGRI, NHLBI, NICHD, NCCIH, and NSF, among others. In 2010 Dr. Perlis was awarded the Depression and Bipolar Support Alliance's Klerman Award; he now serves as a scientific advisor to the DBSA.



Scott Beach, M.D., FACLP
Massachusetts General Hospital

Dr. Scott R. Beach is the Program Director for the MGH/McLean Adult Psychiatry Residency, an attending psychiatrist on the MGH Psychiatry Consultation and Acute Psychiatric Services, and an Associate Professor of Psychiatry at Harvard Medical School. He attended the University of Virginia School of Medicine and completed a residency in Adult Psychiatry at the University of Virginia. He finished a fellowship in Consultation-Liaison Psychiatry at the Massachusetts General Hospital. Dr. Beach has developed clinical and scholarly areas of expertise in QT prolongation and psychiatric medications, catatonia and related syndromes, neuropsychiatric effects of COVID-19, and deception syndromes. He has authored over 50 peer-reviewed publications and more than 25 book chapters, and has edited two books.



Eric Lenze, M.D.
Healthy Mind Lab

Dr. Lenze is the Wallace & Lucille Renard Professor of Psychiatry and Director of the Healthy Mind Lab at Washington University School of Medicine in St. Louis.

Dr. Lenze is a clinical trialist who has successfully advanced evidence-based medicine for depression, anxiety, and cognitive disorders in older adults:

- He advanced the concept of the Precision Clinical Trial, a framework for using clinical trials to advance precision medicine in neurobehavioral disorders.
- He incorporated mobile and internet technology into clinical trials, including the fully remote STOP COVID trial, which recruited a national patient sample from a single expert investigative site.
- Improving the outcomes of medically ill rehabilitating and peri-operative older adults with depression and anxiety has culminated in Enhanced Medical Rehabilitation, an evidence-based engagement intervention which improves functional outcomes in older adults undergoing post-acute rehabilitation. In 2021, he founded the first-ever Center for Perioperative Mental Health (funded by NIMH).

Update From Federal and Other Funding Agencies

Thursday, June 2nd: 10:00 a.m. – 12:30 p.m.



Josh Gordon, M.D., Ph.D.
National Institute of Mental Health

Joshua A. Gordon, M.D., Ph.D. is the Director of the National Institute of Mental Health (NIMH), the lead federal agency for research on mental disorders. He oversees an extensive research portfolio of basic and clinical research that seeks to transform the understanding and treatment of mental illnesses, paving the way for prevention, recovery, and cure.

Dr. Gordon pursued a combined M.D.-Ph.D. degree at the University of California, San Francisco (UCSF). Medical school coursework in psychiatry and neuroscience convinced him that the greatest need, and greatest promise, for biomedical science was in these areas.

During his Ph.D. thesis with Dr. Michael Stryker, Dr. Gordon pioneered the methods necessary to study brain plasticity in the mouse visual system. Upon completion of the dual degree program at UCSF, Dr. Gordon went to Columbia University for his psychiatry residency and research fellowship because of the breadth and depth of the research opportunities there. Working with Dr. Rene Hen, Dr. Gordon and colleagues studied the role of the hippocampus, a brain structure known to be important for memory and emotional processes associated with anxiety and depression. He joined the Columbia faculty in 2004 as an assistant professor in the Department of Psychiatry.

Dr. Gordon's research focuses on the analysis of neural activity in mice carrying mutations of relevance to psychiatric disease. His lab studied genetic models of these diseases from an integrative neuroscience perspective, focused on understanding how a given disease mutation leads to a behavioral phenotype across multiple levels of analysis. To this end, he employs a range of systems neuroscience techniques, including in vivo imaging, anesthetized and awake behavioral recordings, and optogenetics, which is the use of light to control neural activity. His research has direct relevance to schizophrenia, anxiety disorders, and depression.

In addition to his research, Dr. Gordon was an associate director of the Columbia University/New York State Psychiatric Institute Adult Psychiatry Residency Program, where he directed the neuroscience curriculum and administered research training programs for residents. Dr. Gordon also maintained a general psychiatric practice, caring for patients who suffer from the illnesses he studied in his lab at Columbia.

Dr. Gordon's work has been recognized by several prestigious awards, including the Brain and Behavior Research Foundation – NARSAD Young Investigator Award, the Rising Star Award from the International Mental Health Research Organization, the A.E. Bennett Research Award from the Society of Biological Psychiatry, and the Daniel H. Efron Research Award from the American College of Neuropsychopharmacology.



George Koob, Ph.D.

National Institute on Alcohol Abuse and Alcoholism

George F. Koob, is Director of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) as of January 27, 2014. He is also a Senior Investigator at the Intramural Research Program of the National Institute on Drug Abuse where he directs the Neurobiology of Addiction Laboratory in the Integrative Neurosciences Research Branch. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 750 peer reviewed papers and several books including the “Neurobiology of Addiction,” a comprehensive treatise on emerging research in the field, and a textbook for upper division undergraduates and graduate students called “Drugs, Addiction and the Brain.” He has mentored or co-mentored 13 Ph. D students and 84 post-doctoral fellows and 11 K99’s. He received his Ph.D. in Behavioral Physiology from Johns Hopkins University in 1972. He spent much of his early career at the Scripps Research Institute as the Director of the Alcohol Research Center, and as Professor and Chair of the Scripps’ Committee on the Neurobiology of Addictive Disorders. Dr. Koob is the recipient of many honors, including membership in the National Academy of Medicine (USA) and award of the Legion of Honor (France).



Holly Ramsawh, Ph.D.

Patient-Centered Outcomes Research Institute

Dr. Ramsawh is a Senior Program Officer within the Science division at the Patient-Centered Outcomes Research Institute (PCORI). In this role, she supports the Clinical Effectiveness Research priority area. Her responsibilities include strategic decision-making to advance PCORI’s patient-centered research agenda, developing funding announcements, and awarding and managing a portfolio of funded projects.

Before PCORI, she was a research psychologist with the Henry M. Jackson Foundation for the Advancement of Military Medicine, and a research assistant professor in the Department of Psychiatry at the Uniformed Services University of the Health Sciences. In this position, she conducted research in the areas of psychiatric epidemiology and military mental health, including risk factors

for suicidal behavior in the military. In addition, she has clinical and research expertise in the phenomenology, course, and cognitive-behavioral treatment of anxiety disorders and insomnia.

Dr. Ramsawh received a PhD in clinical psychology from Boston University. She completed her pre-doctoral internship at Zucker Hillside Hospital/Long Island Jewish Medical Center, and postdoctoral fellowships at both Brown University and the University of California San Diego. She maintains licensure as a psychologist in the state of California.



Ivan Montoya, M.D., M.P.H.
National Institute on Drug Abuse

Dr. Montoya is a psychiatrist and epidemiologist who specializes in the development of therapeutics for Substance Use Disorders (SUDs). He provides programmatic oversight for grants and contracts in DTMC, and manages activities and resources of the Division involved in the research of new therapeutics and the medical consequences of SUDs. He also provides medical oversight to grants and contracts, as well as supports the development and implementation of policies and procedures for data and medical safety monitoring of clinical trials. He leads the NIH's Helping to End Addiction Long Term (HEAL) Initiative to develop new interventions to prevent and treat opioid use disorders and overdose. Previous experience includes seven years as a clinical investigator in the Intramural Research Program of NIDA, and four years in academia. He joined NIDA Extramural Research Program in December of 1999.



Miriam E. Delphin-Rittmon, Ph.D.

Substance Abuse and Mental Health Services

Dr. Miriam E. Delphin-Rittmon is currently Assistant Secretary for Mental Health and Substance Use in the U.S. Department of Health and Human Services and the Administrator of the Substance Abuse and Mental Health Services Administration. She previously served as Commissioner of the Connecticut Department of Mental Health and Addiction Services (DMHAS) and served in this role for six years. Prior positions held at DMHAS include Deputy Commissioner, Senior Policy Advisor and Director of the department's Office of Multicultural Healthcare Equity. In her role as Commissioner, Dr. Delphin-Rittmon was committed to promoting recovery oriented, integrated, and culturally responsive services and systems that foster dignity, respect, and meaningful community inclusion.

Prior to her current appointment, Dr. Delphin-Rittmon was an Adjunct Associate Professor at Yale University where she served on faculty for the past 20 years. While at Yale Dr. Delphin-Rittmon served as the Director of Cultural Competence and Research Consultation with the Yale University Program for Recovery and Community Health.

In May 2014, Dr. Delphin-Rittmon completed a two-year White House appointment working as a Senior Advisor to the Administrator of the Substance Abuse and Mental Health Services Administration (SAMHSA) with the U.S. Department of Health and Human Services. While at SAMHSA, she worked on a range of policy initiatives addressing behavioral health equity, workforce development, and healthcare reform.

Through her 20 year career in the behavioral health field Dr. Delphin-Rittmon has extensive experience in the design, evaluation, and administration of mental health, substance use and prevention services and systems and has received several awards for advancing policy in these areas. Most recently, she received the 2019 State Service Award from the National Association of State Drug and Alcohol Directors and the 2016 Mental Health Award for Excellence from the United Nations Committee on Mental Health.

She received her B.A. in Social Science from Hofstra University in 1989, her M.S. and Ph.D. in Clinical Psychology from Purdue University 1992 and 2001, respectively, and completed a postdoctoral fellowship in clinical community psychology at Yale University in 2002.



Jana Drgonova, Ph.D.
Veterans Affairs

Jana Drgonova, Ph.D., is a Scientific Program Manager at the Office of Research and Development, Veterans Health Administration. She has joined VA in 2019 to oversee the research portfolio on alcohol and substance use disorders, pain, and preclinical studies in mental health. She is also developing a research program on medical marijuana, cannabinoids and synthetic compounds that act on the endocannabinoid system. Dr. Drgonova came

to VA from the Center for Scientific Review (CSR) of the National Institutes of Health, where she oversaw the Neurotoxicology and Alcohol Study Section as its Scientific Review Officer. Prior to joining CSR, she was an intramural staff scientist at the National Institute on Drug Abuse, where she studied molecular, genetic and cellular mechanisms of drug addiction. Dr. Drgonova earned her Ph.D. in biochemistry from the Slovak Technical University, studying cell morphogenesis and focusing on the role of small GTP-binding proteins in cell cycle progression and cell polarization.

Clinical Updates in Psychopharmacology

Thursday, June 2nd: 2:00 p.m. – 3:30 p.m.



Andrew Krystal, M.D.
University of California San Francisco

Andrew Krystal is the Ray and Dagmar Dolby Distinguished Professor in the UCSF Department of Psychiatry and Behavioral Sciences. He is also Director of the Dolby Family Center for Mood Disorders and the Clinical and Translational Sleep Research Laboratory and is Vice-Chair for Research. He is a leader in clinical and translational research in sleep and mood disorders and is best known for biomarker-based development of novel therapies for

these conditions.



Oliver Freudenreich, M.D.
Massachusetts General Hospital

Oliver Freudenreich, MD, FACLP an Associate Professor of Psychiatry at Harvard Medical School and a Psychiatrist at Massachusetts General Hospital (MGH), serves as co-director of the MGH Psychosis Clinical and Research Program and directs the MGH Fellowship in Public and Community Psychiatry. His academic interest lies in the area of optimal psychopharmacological treatment for schizophrenia, including the development of innovative treatments and management of treatment-resistant psychosis. In addition to his clinical and clinical trial expertise in schizophrenia, Dr. Freudenreich provides psychiatric consultations for medically complex patients with serious mental illness and for diagnostically difficult cases with psychosis. He has published extensively in his areas of interest and has written a handbook on psychotic disorders; its second edition was published in 2020. Dr. Freudenreich teaches and speaks on a regular basis at international and national meetings.




Michael E. Thase, M.D.
University of Pennsylvania

Dr. Michael Thase joined the faculty of the Perelman School of Medicine at the University of Pennsylvania in January, 2007 as Professor of Psychiatry after more than 27 years at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic. Dr. Thase's research focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder. A 1979 graduate of the Ohio State University College of Medicine, Dr. Thase is a Distinguished Fellow of the American Psychiatric Association, a Founding Fellow of the Academy of Cognitive Therapy, a member of the Board of Directors of the American Society of Clinical Psychopharmacology, and Vice Chairman of the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase has been elected to the membership of the American College of Psychiatrists and the American College of Neuropsychopharmacology. Dr. Thase has authored or co-authored more than 500 scientific articles and book chapters, as well as 15 books.

Regulatory Wrap-Up

Friday, June 3rd: 10:15 a.m. – 11:45 a.m.



Maria Tome

European Medicines Agency

See Dr. Tome's biography on page 8.



Tiffany Farchione, M.D.

US Food and Drug Administration

See Dr. Farchione's biography on page 8.



Bernard Fischer, M.D.

U.S. Food and Drug Administration

Dr. Fischer is a psychiatrist and Deputy Director for the Division of Psychiatry in the Office of New Drugs at the U.S. Food and Drug Administration (FDA). Prior to coming to the FDA, he spent more than 10 years in academic medicine researching schizophrenia at the Maryland Psychiatric Research Center (MPRC) and the Department of Veterans Affairs. Dr. Fischer earned his medical degree from the Medical College of Virginia. He completed a 5-year research/clinical residency in psychiatry at the University of Maryland/Sheppard Pratt followed by a post-doctoral fellowship in schizophrenia research at the MPRC. He holds a master's degree in biomedical ethics and has been board certified in both psychiatry and addiction medicine. He has authored or co-authored over 50 scientific publications.



Marion Haberkamp, M.D.

Federal Institute of Drugs and Medical Devices

Dr. Marion Haberkamp is a medical doctor and board certified internist with a neurological background. After working as a clinical senior assessor in the area of CNS she is head of the section Neurology, Psychiatry and Ophthalmology at the Federal Institute of Drugs and Medical devices (BfArM) in Bonn Germany since 2017. As a member of the Central System Working Party (CNSWP) at the European Medicines Agency (EMA), Amsterdam she is involved in the drafting of regulatory guidelines. As a long-time member and now expert of the Scientific Advice Working Party (SAWP) she has experience providing central advice on neurological and psychiatric drug developments.

Steering Committee Chairs



Susan G. Kornstein, M.D.



Mark H. Rapaport, M.D.

Program Chairs



Lee Cohen, M.D.



Erika Saunders, M.D.

New Investigator Award Program Chairs



Mark H. Rapaport, M.D.



Christopher Sarampote, Ph.D.

Steering Committee Members

Ross Baker, Ph.D.
VistaGen Therapeutics

Lee Cohen, M.D.
Massachusetts General Hospital

★Lori Davis, M.D.
Tuscaloosa VA Medical Center

Bryan Dirks, M.D.
ACADIA Pharmaceuticals Inc.

Daniel Falk, Ph.D.
National Institute of Alcohol Abuse
and Alcoholism

★Tiffany Farchione, M.D.
US Food and Drug Administration

Marlene Freeman, M.D.
Massachusetts General Hospital,
Ammon-Pinizzotto Center for
Women's Mental Health

David J. Kupfer, M.D.
University of Pittsburgh School of
Medicine

Valentina Mantua, M.D.
Center for Drug Evaluation and
Research, FDA

Stephen Marder, M.D.
Semel Institute at UCLA

Iván Montoya, M.D., M.P.H.
National Institute on Drug Abuse

★Francisco Moreno, M.D.
University of Arizona

John Newcomer, M.D.
Thriving Mind South Florida

Luca Pani, M.D.
University of Miami

★Erika Saunders, M.D.
Penn State College of Medicine,
Penn State Milton S. Hershey
Medical Center

★Madhukar Trivedi, M.D.
University of Texas Southwestern
Medical Center

★ New Investigator Alumni

*Representing ASCP CME Committee

Program Committee

Scott Aaronson, M.D.*
Sheppard Pratt Health Systems

Mohammed Ahmed, M.D.
University of California, San Diego

Amit Anand, M.D.
Cleveland Clinic Lerner School of
Medicine of Case Western University

Pratik Bahekar, M.D.
Yale-New Haven Psychiatric Hospital

★ Anahita Bassir Nia, M.D.*
Yale University School of Medicine

Theadia L. Carey, M.D.*
Detroit Wayne Health Authority

Lawrence Cohen, Pharm.D.
University of North Texas Health
Science Center

Lynn Crismon, Pharm.D.*
The University of Texas at Austin

Larry Culpepper, M.D., M.P.H.
Boston University

★Cristina Cusin, M.D.
Massachusetts General Hospital

Maurizio Fava, M.D.
Massachusetts General Hospital

★ Bharathi Gadad, Ph.D.
Texas Tech University Health
Science Center

Bradley Gaynes, M.D.*
University of North Carolina

★ Srinath Gopinath, M.D.
UCONN Health Center

Vikas Gupta, M.D., M.P.H.*
ECU

Ahmad Hameed, M.D.
Pennsylvania State College of
Medicine

Usman Hameed, M.D.
Penn State Hersey Medical Center

★ Ebrahim Haroon, M.D.
Emory University School of Medicine

Michael Henry, M.D.
Massachusetts General Hospital

★ Dan Iosifescu, M.D.
Nathan S Kline Institute/New York
University School of Medicine

★ Ayana Jordan, M.D., Ph.D.
Yale University School of Medicine

Susan G. Kornstein, M.D.
Virginia Commonwealth University

★ Rajnish Mago, M.D.*
Simple and Practical Mental Health

Sanjay Mathew, M.D.
Baylor College of Medicine

★ **New Investigator Alumni** ***Representing ASCP CME Committee**

Program Committee (Continued)

★ Brian Mickey, M.D., Ph.D.
University of Utah School of
Medicine

★ Francisco Moreno, M.D.
University of Arizona

Charles Nemeroff, M.D., Ph.D.
The University of Texas at Austin

Andrew Nierenberg, M.D.
Massachusetts General Hospital

Minkyung Park, M.D.
UTSW Medical Center Dallas

Mark Pollack, M.D.
Rush University Medical Center

★ Rajiv Radhakrishnan, M.D.
Yale School of Medicine

★ Jair Soares, M.D., Ph.D.
University of Texas School of
Medicine at Houston

Oleg Tcheremissine, M.D.
Atrium Health

★ Madhukar Trivedi, M.D.
University of Texas Southwestern
Medical Center

★ Christine Ulbricht, M.P.H., Ph.D.
University of Massachusetts Medical
School

★ Carlos A. Zarate, M.D.
National Institute of Mental Health

Mark Zimmerman, M.D.*
Brown University

New Investigator Award Program Committee

★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital

★ Lori Davis, M.D.
Tuscaloosa VA Medical Center

★ Michael Davis, M.D., Ph.D.
US Food and Drug Administration

★ Tiffany Farchione, M.D.
US Food and Drug Administration

Bruce Kinon, M.D.
Cyclerion Therapeutics

Iván Montoya, M.D., M.P.H.
National Institute on Drug Abuse

★ Katharine Phillips, M.D.
Weill Cornell Medical College/New
York-Presbyterian Hospital

Nina R. Schooler, Ph.D.
State University of New York,
Downstate Medical Center

★ Holly A. Swartz, M.D.
University of Pittsburgh School of
Medicine

★ **New Investigator Alumni**

* **Representing ASCP CME Committee**

ASCP Officers and Board

Leslie Citrome, M.D., M.P.H.
ASCP President and Past Treasurer
New York Medical College

★ Joseph F. Goldberg, M.D.*
ASCP President Elect
Icahn School of Medicine at Mount Sinai

★ Madhukar Trivedi, M.D.
ASCP Past President
UT Southwestern Medical Center

Trisha Suppes, M.D., Ph.D.
ASCP Treasurer
Stanford University

★ Holly A. Swartz, M.D.
ASCP Treasurer Elect
University of Pittsburgh School of Medicine

Scott Aaronson, M.D.*
Sheppard Pratt Health System

★ Christoph U. Correll, M.D.
The Zucker Hillside Hospital

Marlene Freeman, M.D.
Massachusetts General Hospital,
Ammon-Pinizzotto Center for
Women's Mental Health

★ Dan Iosifescu, M.D.
Nathan S Kline Institute/New York
University School of Medicine

John Kane, M.D.
The Zucker Hillside Hospital

Susan G. Kornstein, M.D.
Virginia Commonwealth University,
Board Member-elect

Matthew Macaluso, D.O.
University of Alabama at Birmingham

Stephen Marder, M.D.
Semel Institute at UCLA

Sanjay Mathew, M.D.
Baylor College of Medicine

★ Francisco Moreno, M.D.
University of Arizona

★ George Papakostas, M.D.
Massachusetts General Hospital

★ Katharine Phillips, M.D.
Weill Cornell Medical College/New
York-Presbyterian Hospital

★ **New Investigator Alumni** ***Representing ASCP CME Committee**

[illegible]

Registration Desk* Hours:

Monday	1:00 p.m. – 5:00 p.m.
Tuesday	7:30 a.m. – 6:00 p.m.
Wednesday	7:30 a.m. – 7:00 p.m.
Thursday	7:30 a.m. – 6:00 p.m.
Friday	7:30 a.m. – 12:00 p.m.

*The registration/meeting information desk is located in the East Foyer, outside of the Princess Ballroom.

Speaker Ready Room* Hours:

Monday	1:00 p.m. – 5:00 p.m.
Tuesday - Thursday	7:30 a.m. – 6:00 p.m.
Friday	7:30 a.m. – 10:30 a.m.

*The Speaker Ready Room is located in the Bourbon 11 meeting room.

The meeting organizers ask that all speakers upload their slides no later than 24 hours prior to their scheduled presentation time.

ASCP Wi-Fi

SSID: Fairmont-Meeting

Access PIN: ASCP2022

Americans with Disabilities Act - It is the policy of ASCP not to discriminate against any person on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in order to fully participate in this continuing education activity, please call the Executive Office at 615-649-3085 or send an email to info@ascpp.org.

Discounts – All ASCP Annual Meeting attendees who booked their room at the Fairmont Scottsdale Princess through the ASCP meeting website will have the following resort amenities complimentary:

- Unlimited basic internet access in your guest rooms and resort public areas.
- Any local and 1-800 access calls from your guest room.
- Complimentary self-parking for one vehicle per room.
- Complimentary half-day admission to Trailblazers kid's adventure club access for up to three children.
- Access to 24-hour Fairmont Fitness Center.
- On-site shuttle transportation service (guest rooms, restaurants, spa, pool and meeting space).
- 50% discount off Well & Being Spa daily access fee including complimentary fitness and wellness classes, waterfall treatment pool, sauna, and rooftop pool.
- 10% discount off a 60, 90 or 120 minute personal service at Well & Being Spa.

ASCP | Meeting Announcements

Recordings – All plenaries, panel sessions, and select other sessions, unless otherwise noted, will be recorded and available on the virtual conference platform for 30 days post conference. All registered attendees will have access to the virtual platform and recordings through Friday, July 01, 2022.

ASCP Membership - If you would like to join ASCP, you can log onto our website at <https://www.ascpp.org/> and register online. Membership applications are available at the ASCP registration desk, located in the East Princess Foyer. You may also contact the ASCP office at 615-649-3085 to request one.

Continuing Education Credits

Disclosures are available for all ASCP Annual Meeting presenters online at www.ASCPMeeting.org.

American Society of Clinical Psychopharmacology (ASCP) 2022 ASCP Annual Meeting

Live in Scottsdale, AZ and Virtual: May 31 – June 03, 2022

Enduring Material (Pre-recorded): June 03 – July 01, 2022

Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Society of Clinical Psychopharmacology (ASCP). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) / Nurses (ANCC) / Pharmacists (ACPE) Credit Designations

Live Content - Amedco LLC designates this live activity for a maximum of 17.75 *AMA PRA Category 1 Credits™* for physicians, 17.75 ANCC contact hours for nurses and 17.75 knowledge-based CPE contact hours for pharmacists.

Recorded/Enduring Content - Amedco LLC designates this enduring activity for a maximum of 36.00 *AMA PRA Category 1 Credits™* for physicians, 36.00 ANCC contact hours for nurses and 36.00 knowledge-based CPE contact hours for pharmacists. **NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.**

Learners should claim only the credit commensurate with the extent of their participation in the activity.

The 17.75 live hours cannot also be claimed as enduring hours.

Psychologists (APA) Credit Designation

Live Content - Amedco LLC designates this live activity for a maximum of 17.75 Psychologist contact hours.

Recorded/Enduring Content - Amedco LLC designates this enduring material activity for a maximum of 36.00 Psychologist contact hours.

The 17.75 live hours cannot also be claimed as enduring hours.

New York Board for Psychology (NY PSY)

Live Content - Amedco is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0031. Maximum of 17.75 hours.

Recording/Enduring Content - Amedco is recognized by the New York State Education Department's State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY-0031. Maximum of 36.00 hours.

The 17.75 live hours cannot also be claimed as enduring hours.

Physician Assistants

PAs may claim a maximum of 17.75 live Category 1 credits and a maximum of 36.00 enduring Category 1 credits for completing this activity. NCCPA accepts *AMA PRA Category 1 Credit™* from organizations accredited by ACCME or a recognized state medical society.

The 17.75 live hours cannot also be claimed as enduring hours.

Nurse Practitioners

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit.

ASCP | Meeting Announcements

ASCP would like to acknowledge the generosity of the following companies whose unrestricted educational grants have contributed to the overall quality of this meeting:

**Intra-Cellular Therapies
Sunovion**

2023 ASCP Annual Meeting

Save the Date



The 2023 ASCP Annual Meeting will take place May 30 – June 02, 2023, at the Loews Miami Beach Hotel in Miami, Florida. Details regarding abstract submission for the 2023 Annual Meeting will be released in September 2022.

AT-A-GLANCE

Sunday, May 29, 2022

6:00 p.m. - 7:00 p.m. **New Investigator Award (NIA) Meet and Greet (Invitation Only)**
Moor 1

Monday, May 30, 2022

8:00 a.m. - 4:55 p.m. **NIA Workshop (Invitation Only)**
Palomino Ballroom 9-10

1:00 p.m. - 5:00 p.m. **Registration**
Princess East Foyer Desk

1:00 p.m. - 5:00 p.m. **Speaker Ready Room**
Bourbon 11

7:00 p.m. - 9:00 p.m. **2020/2021 NIA Dinner**
Moor 1

Monday

[illegible]

FULL SCHEDULE

Monday, May 30, 2022

8:00 a.m. - 4:55 p.m.

NIA Workshop (Invitation Only)

Palomino Ballroom 9-10

Co-Chairs: Mark Rapaport, University of Utah Huntsman Mental Health Institute
Chris Sarampote, National Institute of Mental Health

The ASCP Annual Meeting offers a special program for New Investigators in an effort to promote the education and training of junior investigators in psychopharmacology. Established investigators were asked to nominate individuals who may be interested in a research career in psychopharmacology for this special program. These nominees submitted an abstract describing their current research or area of research interest, a letter of recommendation from their chair or mentor, a career statement and a curriculum vitae. The selection of awardees was based upon the scientific merit of the abstract, the level of training of the nominee and a committee of internal and external reviewers' assessment of the relative value of the specialized program to each applicant at this time in his/her career. The awardees will participate in this special educational workshop and present their posters during the scheduled poster sessions and orals during the Individual Research Reports on Tuesday, May 31, 2022. In addition, they will receive a travel expense award and a certificate acknowledging their participation in the program at an awards ceremony on Tuesday evening, May 31, 2022. This year marks the 30th year of the New Investigator program with 20 New Investigator awardees that are indicated with a ribbon in the poster session of this program; they will also be notated with a ribbon icon in the program book.

Faculty

Michael Davis, US Food and Drug Administration

Tiffany Farchione, US Food and Drug Administration

Bruce Kinon, Cycleron Therapeutics

Iván Montoya, National Institute on Drug Abuse

Katharine Phillips, Weill Cornell Medical College/NewYork-Presbyterian Hospital

Nina Schooler, SUNY Downstate Medical Center

Holly Swartz, M.D., University of Pittsburgh School of Medicine

7:00 p.m. - 9:00 p.m.

2020/2021 New Investigator Awardee Dinner
Moor 1

AT-A-GLANCE

Tuesday, May 31, 2022

7:30 a.m. - 8:30 a.m. **NIA Breakfast Roundtable (Invitation Only)**
Castile 1

7:30 a.m. - 9:00 a.m. **Morning Break**
Princess East Foyer

7:30 a.m. - 6:00 p.m. **Registration**
Princess East Foyer Desk

7:30 a.m. - 6:00 p.m. **Speaker Ready Room**
Bourbon 11

8:30 a.m. - 9:00 a.m. **Conference Opening**
Salon A-E

9:00 a.m. - 10:30 a.m. **Panel Sessions**

*Ketamine/Esketamine in Psychiatric Disorders Across the Lifespan: Therapeutic Potential and the Underlying Biological Mechanisms+	Biomarkers in Clinical Studies: Is the Juice Worth the Squeeze?+	*Improving Schizophrenia Treatment Outcome: New Data and New Strategies
<i>Salon A-E</i>	<i>Princess Ballroom H</i>	<i>Princess Ballroom I</i>

10:30 a.m. - 10:45 a.m. **Break**
Princess East Foyer

10:45 a.m. – 12:15 p.m. **Panel Sessions**

*Topics in Reproductive Psychiatry	Novel Pharmacotherapies for Post-Traumatic Stress Disorder	Major Depressive Disorder with Insomnia Symptoms: Characterizing Clinical Burden and Elucidating Biological Mechanisms to Drive Novel Treatment Development+	*Differential Diagnosis of Bipolar II Disorder: What Do We Know and What Does It Mean for an Expert by Experience
<i>Princess Ballroom F</i>	<i>Princess Ballroom G</i>	<i>Princess Ballroom H</i>	<i>Princess Ballroom I</i>

12:15 p.m. - 1:45 p.m. **Inclusivity Committee Lunch (RSVP Only)**
Princess Ballroom H

2:00 p.m. - 4:00 p.m. **Pharmaceutical Pipelines+**
Salon A-E

4:00 p.m. - 4:15 p.m. **Break**
Princess East Foyer

4:15 p.m. - 5:30 p.m. **Individual Research Reports**

Brain Health Outcome Studies and Novel Potential Interventions+	Depression, Psychosis and Substance Use Disorders (SUD) on the Edge: Impacts on Brain Structures, Social Interactions Impact Outcomes Based on Neighborhoods, and Ketamine for Late-Life TRD to Boot	Imaging, Pregnancy Registry and AI: Different Approaches in Mental Health	Tracking Molecular, Physiological, and Behavioral Outcomes in Clinical Studies: Implications for Personalized Therapies and Trial Design
<i>Princess Ballroom F</i>	<i>Princess Ballroom G</i>	<i>Princess Ballroom H</i>	<i>Princess Ballroom I</i>

6:15 p.m. - 7:45 p.m. **New Investigator Awards Ceremony (Invitation Only)**
Arabian A/B and Patio

***Of Special Interest To Clinicians +No CME Credits Offered**

FULL SCHEDULE

Tuesday, May 31, 2022

7:30 a.m. - 8:30 a.m.	NIA Breakfast Roundtable (Invitation Only) <i>Castile 1</i>
7:30 a.m. - 9:00 a.m.	Morning Break <i>Princess East Foyer</i>
7:30 a.m. - 6:00 p.m.	Registration <i>Princess East Foyer Desk</i>
7:30 a.m. - 6:00 p.m.	Speaker Ready Room <i>Bourbon 11</i>
8:30 a.m. - 9:00 a.m.	Conference Opening <i>Salon A-E</i>

Panel Sessions

9:00 a.m. – 10:30 a.m.	*Ketamine/Esketamine in Psychiatric Disorders Across the Lifespan: Therapeutic Potential and the Underlying Biological Mechanisms+ <i>Salon A-E</i>
------------------------	---

Chair: Madhukar Trivedi, University of Texas Southwestern Medical Center

Co-Chair: Manish Jha, University of Texas Southwestern Medical Center

Discussant: Alan Schatzberg, Stanford University School of Medicine

9:00 a.m. – 9:10 a.m.	Introduction
9:10 a.m. - 9:25 a.m.	Irritability in Adults with Treatment-Resistant Depression (TRD) and Treatment Outcomes with Intranasal Esketamine Ibrahim Turkoz, Janssen R and D, LLC
9:25 a.m. - 9:40 a.m.	A Bayesian Adaptive Randomization Trial to Optimize Intravenous Ketamine Dosing for Late-Life Treatment-Resistant Depression Sanjay J. Mathew, Baylor College of Medicine and Michael E. DeBakey VA Medical Center

**Of Special Interest To Clinicians +No CME Credits Offered*

9:00 a.m. – 10:30 a.m. (continued) ***Ketamine/Esketamine in Psychiatric Disorders Across the Lifespan: Therapeutic Potential and the Underlying Biological Mechanisms+**
Salon A-E

9:40 a.m. - 9:55 a.m. **Role of Stress and Inflammation in the Mechanisms of Depression and Therapeutic Effects of Ketamine**
James Murrough, Icahn School of Medicine at Mount Sinai

9:55 a.m. - 10:10 a.m. **Ketamine for Pediatric Treatment Resistant Depression and Suicidality: Advances and Challenges**
Jennifer Dwyer, Boehringer Ingelheim

10:10 a.m. – 10:30 a.m. **Discussion**

9:00 a.m. – 10:30 a.m. **Biomarkers in Clinical Studies: Is the Juice Worth the Squeeze?+**
Princess Ballroom H

Chair: William Potter, Foundation of the National Institutes of Health

Co-Chair: Larry Ereshefsky, Apex Innovative Sciences

Discussant: Brett English, Apex Innovative Sciences

9:00 a.m. – 9:10 a.m. **Introduction**

9:10 a.m. - 9:30 a.m. **How Biomarkers Can Inform Trial Design or Trial Outcomes: A Program Officer's Perspective on Portfolio Need**
Margaret Grabb, National Institute of Mental Health

9:30 a.m. - 9:50 a.m. **The Potential of Neurogenetic Disorders with Neuropsychiatric Presentation to Improve the Juice Concentration for the Biomarker Squeeze**
Raquel Gur, University of Pennsylvania

9:50 a.m. - 10:10 a.m. **Enabling Precision Psychiatry: Why Should Biomarkers be Incorporated into CNS Drug Discovery from Pre-clinical Research to Clinical Application and What do they Deliver?**
Scott Hobson, Boehringer Ingelheim

10:10 a.m. – 10:30 a.m. **Discussion**

**Of Special Interest To Clinicians +No CME Credits Offered*

9:00 a.m. – 10:30 a.m. ***Improving Schizophrenia Treatment Outcome: New Data and New Strategies**
Princess Ballroom I

Chair: Ira Glick, Stanford University School of Medicine

Discussant: Stephen Marder, Semel Institute at UCLA

9:00 a.m. – 9:10 a.m. **Introduction**

9:10 a.m. - 9:25 a.m. **Interpreting Meta-Analysis of Antipsychotics**
John Davis, University of Illinois at Chicago

9:25 a.m. - 9:40 a.m. **An Update on the Pharmacologic Treatment of Early Psychosis**
Donald Goff, NYU Langone Medical Center

9:40 a.m. - 9:55 a.m. **Update on Strategies for Treatment Resistant Psychosis**
Jean-Pierre Lindenmayer, New York University
Grossman School of Medicine

9:55 a.m. - 10:10 a.m. **Should Antipsychotic Medications for Schizophrenia Be Given for a Lifetime? Summary of Four Naturalistic, 6-53 Year Long-Term, Follow-Up Studies of Antipsychotic Treatment for Schizophrenia**
Ira Glick, Stanford University School of Medicine

10:10 a.m. – 10:30 a.m. **Discussion**

10:30 a.m. - 10:45 a.m. **Break**
Princess East Foyer

Panel Sessions

10:45 a.m. - 12:15 p.m. *Topics in Reproductive Psychiatry
Princess Ballroom F

Chair: Jennifer Payne, University of Virginia

Discussant: Lauren Osborne, Johns Hopkins University School of Medicine

10:45 a.m. – 10:55 a.m. **Introduction**

10:55 a.m. - 11:15 a.m. **Neuroactive Steroids: Mechanism of Action and Investigational Treatment for Depressive Disorders**

Mercedes Szpunar, Massachusetts General Hospital, Center for Women's Mental Health

11:15 a.m. - 11:35 a.m. **Neuroactive Steroids in "Reproductive Depression"**

Jennifer Payne, University of Virginia

11:35 a.m. - 11:55 a.m. **Neuroendocrine Factors Mediate Sexual Dysfunction and Depression**

Anita H. Clayton, University of Virginia

11:55 a.m. – 12:15 p.m. **Discussion**

10:45 a.m. – 12:15 p.m. Novel Pharmacotherapies for Post-Traumatic Stress Disorder
Princess Ballroom G

Chair: George Papakostas, Massachusetts General Hospital

Co-Chair: Ann Rasmusson, Boston University School of Medicine

Discussant: Maurizio Fava, Massachusetts General Hospital

10:45 a.m. – 10:55 a.m. **Introduction**

10:55 a.m. - 11:10 a.m. **Role of Gabaergic and Related NMDA Receptor-Active Neurosteroids in Novel Treatment Development for Posttraumatic Stress Disorder (PTSD)**

Ann Rasmusson, Boston University School of Medicine

***Of Special Interest To Clinicians +No CME Credits Offered**

10:45 a.m. – 12:15 p.m. (continued) Novel Pharmacotherapies for Post-Traumatic Stress Disorder

Princess Ballroom G

11:10 a.m. - 11:25 a.m. CBD in the Treatment of Posttraumatic Stress Disorder

Michael Telch, The University of Texas At Austin

11:25 a.m. - 11:40 a.m. Potential of Intranasal Neuropeptide Y for Prevention and Treatment of PTSD and Associated Neuropsychiatric Disorders

Esther Sabban, New York Medical College

11:40 a.m. - 11:55 a.m. Review of the Current PTSD Pipeline

George Papakostas, Massachusetts General Hospital

11:55 a.m. – 12:15 p.m. Discussion

10:45 a.m. - 12:15 p.m. Major Depressive Disorder With Insomnia Symptoms: Characterizing Clinical Burden and Elucidating Biological Mechanisms to Drive Novel Treatment Development+

Princess Ballroom H

Chair: Manish Jha, University of Texas Southwestern Medical Center

Discussant: Sanjay J. Mathew, Baylor College of Medicine and Michael E. DeBakey VA Medical Center

10:45 a.m. – 10:55 a.m. Introduction

10:55 a.m. - 11:15 a.m. Suicide Ideation, Nocturnal Wakefulness and Ketamine

Elizabeth Ballard, National Institute of Mental Health

11:15 a.m. - 11:35 a.m. The Impact of Insomnia Symptoms on Clinical and Patient-Centric Outcomes in Major Depressive Disorder: Findings from the National Health and Wellness Survey

Kruti Joshi, Janssen Scientific Affairs, LLC

10:45 a.m. - 12:15 p.m. (continued) **Major Depressive Disorder With Insomnia Symptoms: Characterizing Clinical Burden and Elucidating Biological Mechanisms to Drive Novel Treatment Development+**
Princess Ballroom H

11:35 a.m. - 11:55 a.m. **Aberrant Reward Function in Adults with Major Depressive Disorder and Moderate/Severe Insomnia and Association with Acute-Phase Treatment Outcomes**
Cherise Chin Fatt, University of Texas Southwestern Medical Center

11:55 a.m. – 12:15 p.m. **Discussion**

10:45 a.m. - 12:15 p.m. ***Differential Diagnosis of Bipolar II Disorder: What Do We Know and What Does It Mean for an Expert by Experience**
Princess Ballroom I

Chair: Trisha Suppes, Stanford University

Co-Chair: Holly Swartz, University of Pittsburgh School of Medicine

Discussant: Trisha Suppes, Stanford University

10:45 a.m. – 10:55 a.m. **Introduction**

10:55 a.m. - 11:15 a.m. **Bipolar II Disorder and Major Depressive Disorder with Mixed Features: The Same or Different?**
Holly Swartz, University of Pittsburgh School of Medicine

11:15 a.m. - 11:35 a.m. **Diagnosing Bipolar Disorder and Borderline Personality Disorder**
Mark Zimmerman, Brown University

11:35 a.m. - 11:55 a.m. ***Insights from an “Expert by Experience” Who has Lived With Bipolar II for Four Decades**
Sara Schley, B Corp

11:55 a.m. – 12:15 p.m. **Discussion**

12:15 p.m. - 1:45 p.m. **Inclusivity Committee Luncheon: Snakes and Ladders in Academic Progression for Underrepresented Faculty (RSVP Only)**
Princess Ballroom H

The Inclusivity Luncheon will be moderated by Francisco Moreno, M.D., University of Arizona and will speak on his own experience of becoming a successful leader and mentor, as well as highlighting challenges and obstacles that could arise throughout one's career and how to overcome them. Followed by a panel consisting of the below speakers in various levels of their career:

- Mahavir Agarwal, M.D., Ph.D., Centre for Addiction and Mental Health (CAMH)
- Crystal Clark, M.D., Northwestern University
- Trisha Suppes, M.D., Ph.D., Stanford University

2:00 p.m. - 4:00 p.m. **Pharmaceutical Pipelines+**
Salon A-E

Chair: Carlos Zarate, National Institute on Mental Health

Co-Chair: Leslie Citrome, New York Medical College

2:00 p.m. - 2:13 p.m. **Brainsonix Technology of Low Intensity Focused Ultrasound Pulse (LIFUP) for Targeted Transcranial Neuromodulation and Delivery of Biological Substances in the Brain**
 Alexander Bystritsky, UCLA Semel Institute for Neuroscience and Human Behavior

2:13 p.m. - 2:26 p.m. **Auricular Transcutaneous Hi-Frequency E-Mmunotherapy Sequences (ATHENS) for Major Depressive Disorder (MDD) with Peripartum Onset with and without Concomitant Antidepressant Use: A Multicenter, Open-Label Pilot Study**
 Kristina Deligiannidis, Zucker Hillside Hospital

2:26 p.m. - 2:39 p.m. **Emerging Profile of TAAR1 Agonist Ulotaront: Preclinical and Clinical Evidence for an Emerging Pharmacological Class**
 Seth C. Hopkins, Sunovion Pharmaceuticals, Inc.

2:00 p.m. - 4:00 p.m.
(continued)

Pharmaceutical Pipelines+
Salon A-E

2:39 p.m. - 2:52 p.m.

A Phase 1/2 Trial of GH001, a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation, in Patients with Treatment-Resistant Depression
Jan Ramaekers, Maastricht University

2:52 p.m. - 3:05 p.m.

COMP360 Psilocybin Therapy in Treatment-Resistant Depression: Results of a Large Randomized Controlled Phase I/II Monotherapy Study and an Exploratory Uncontrolled Adjunctive Therapy Study
Joyce Tsai, COMPASS Pathways Ltd.

3:05 p.m. - 3:18 p.m.

MK-8189, a Novel PDE10A Inhibitor for the Treatment of Schizophrenia
Michael Egan, Merck and Co., Inc.

3:18 p.m. - 3:31 p.m.

Darigabat Reduces Acute Panic and Fear Symptoms Induced by CO2 Inhalation in Healthy Participants
Rachel Gurrell, Cerevel Therapeutics

3:31 p.m. - 3:44 p.m.

Luvadaxistat, an Investigational D-Amino Acid Oxidase inhibitor, was Associated with Signals of Efficacy in Cognitive Impairment Associated with Schizophrenia but Not Negative Symptoms: Results from the Interact Study
Jaskaran Singh, Neurocrine Biosciences

3:44 p.m. - 3:57 p.m.

Efficacy and Safety of Zuranolone Co-Initiated with an Antidepressant in Adults with Major Depressive Disorder: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled Coral Study
Scott Aaronson, Sheppard Pratt

4:00 p.m. - 4:15 p.m.

Break
Princess East Foyer


Individual Research Reports

4:15 p.m. - 5:30 p.m. **Brain Health Outcome Studies and Novel Potential Interventions +**
Princess Ballroom F

Chair: Jair Soares, University of Texas School of Medicine at Houston

4:15 p.m. – 4:20 p.m. **Introduction**

4:20 p.m. - 4:40 p.m. **Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (ZYN2-CL-017)***
Stephen O'Quinn, Zynerva Pharmaceuticals

 4:40 p.m. - 5:00 p.m. **Real-World Clinical Practice Among Patients with Bipolar Disorder and Chronic Kidney Disease on Long-Term Lithium Therapy***
Rakesh Kumar, Mayo Clinic

5:00 p.m. - 5:20 p.m. **Lower Mortality Due to All-Cause in Patients with Major Depression Treated with ECT Compared to Those who Did Not: A National United States Study***
Nagy Youssef, The Ohio State University College of Medicine

5:20 p.m. – 5:30 p.m. **Discussion**




= New Investigator Awardee


**Of Special Interest To Clinicians +No CME Credits Offered*


4:15 p.m. – 5:30 p.m. **Depression, Psychosis and Substance Use Disorders (SUD) on the Edge: Impacts on Brain Structures, Social Interactions Impact Outcomes Based on Neighborhoods, and Ketamine for Late-Life TRD to Boot**
Princess Ballroom G


Chair: Lawrence Cohen, Massachusetts General Hospital

4:15 p.m. – 4:20 p.m. **Introduction**

 **4:20 p.m. – 4:35 p.m.** **Neighborhood Poverty and Hippocampal Volume Among Youth at Clinical High Risk for Psychosis: The Moderating Role of Social Engagement***
Benson Ku, Emory University School of Medicine

 **4:35 p.m. – 4:50 p.m.** **Association Between Depression and Change in Nucleus Accumbens Drug Cue-Reactivity During Extended-Release Naltrexone Treatment for Opioid Use Disorder***
Zhenhao Shi, University of Pennsylvania

 **4:50 p.m. – 5:05 p.m.** **Pre-Infusion Neural Complexity Moderates Clinical Response to Intravenous Ketamine Across 7 Days in Patients with Late-Life Treatment Resistant Depression***
Amanda Tamman, Baylor College of Medicine

 **5:05 p.m. – 5:20 p.m.** **Gliovascular Protein Concentrations in the Periphery Show Differential Changes Depending on Clinical Outcome of Transcranial Magnetic Stimulation for Treatment Resistant Depression: New Star of the Show***
Andrew Fukuda, Brown University/Butler Hospital

5:20 p.m. – 5:30 p.m. **Discussion**


 = New Investigator Awardee

*Of Special Interest To Clinicians +No CME Credits Offered

4:15 p.m. – 5:30 p.m. **Imaging, Pregnancy Registry and AI: Different Approaches in Mental Health**
Princess Ballroom H

Chair: Cristina Cusin, Massachusetts General Hospital

4:15 p.m. – 4:20 p.m. **Introduction**

 4:20 p.m. – 4:40 p.m. **Using Machine Learning to Predict Depression Care Quality at Community Health Centers during the COVID-19 Pandemic**
Evan Goldstein, University of Utah School of Medicine

4:40 p.m. – 5:00 p.m. **Risk of Major Malformations in Infants After First-Trimester Exposure to Benzodiazepines: Results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications**
Mercedes Szpunar, Massachusetts General Hospital, Center for Women's Mental Health

5:00 p.m. – 5:20 p.m. **Functional Connectivity Between the Orbitofrontal Cortex and Putamen in Opioid Use Disorder**
Mario Montelongo, The Menninger Clinic

5:20 p.m. – 5:30 p.m. **Discussion**



= New Investigator Awardee


*Of Special Interest To Clinicians

+No CME Credits Offered


4:15 p.m. – 5:30 p.m. **Tracking Molecular, Physiological, and Behavioral Outcomes in Clinical Studies: Implications for Personalized Therapies and Trial Design**
Princess Ballroom I

Chair: Brian Mickey, University of Utah School of Medicine

4:15 p.m. – 4:20 p.m. **Introduction**

 **4:20 p.m. – 4:35 p.m.** **Application of a Bayesian Adaptive Randomization Design to Optimize Intravenous Ketamine Dosing for Late-Life Treatment Resistant Depression**
Nicholas Murphy, Baylor College of Medicine

4:35 p.m. – 4:50 p.m. **Using Ecological Momentary Assessment to Identify Potentially Non-Adherent Clinical Trials Participants**
Philip Harvey, University of Miami Miller School of Medicine

 **4:50 p.m. – 5:05 p.m.** **Association Between the Epigenetic Lifespan Predictor Grimace and History of Suicide Attempt in Bipolar Disorder**
Camila Nayane de Carvalho Lima, The University of Texas Health Science Center at Houston

5:05 p.m. – 5:20 p.m. **Olanzapine/Samidorphan in Young Adults with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Enlighten-Early Study**
John Kane, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

5:20 p.m. – 5:30 p.m. **Discussion**

6:15 p.m. – 7:45 p.m. **New Investigator Awards Ceremony (Invitation Only)**
Arabian A/B and Patio

 = New Investigator Awardee

**Of Special Interest To Clinicians +No CME Credits Offered*

AT-A-GLANCE

Wednesday, June 1, 2022

6:30 a.m. – 8:00 a.m.	Annual ASCP Fun Run/Walk – All Attendees Welcome (No Prior Sign Up Necessary) <i>Palomino Conference Center North Drive</i>
7:00 a.m. – 8:20 a.m.	Early Career Breakfast (RSVP Only) <i>Princess Ballroom G</i>
7:30 a.m. – 8:30 a.m.	NIA Breakfast Roundtable <i>Castile 1</i>
7:30 a.m. – 9:00 a.m.	Morning Break <i>Princess East Foyer</i>
7:30 a.m. – 6:00 p.m.	Speaker Ready Room <i>Bourbon 11</i>
7:30 a.m. – 7:00 p.m.	Registration <i>Princess East Foyer Desk</i>
8:30 a.m. – 10:00 a.m.	Regulatory Plenary: Psychedelic Drug Development: Perspectives from the FDA and EMA <i>Salon A-E</i>
10:00 a.m. – 10:15 a.m.	Break <i>Princess East Foyer</i>
10:15 a.m. – 11:15 a.m.	ASCP Awards Ceremony and ASCP Lifetime Awardee Talk - Charles Reynolds, M.D.: Looking Back, Giving Thanks, and Moving Forward: Reflections on 50 Years as Physician/Scientist/ Mentor in Geriatric Psychiatry <i>Salon A-E</i>
11:15 a.m. – 1:00 p.m.	Poster Session I with Lunch+ <i>Palomino Ballroom 4-10</i>
11:15 a.m. – 1:00 p.m.	Early Career Networking Tables (Open to all Attendees) <i>Palomino Ballroom 4-10</i>

***Of Special Interest To Clinicians +No CME Credits Offered**

11:30 a.m. - 12:30 p.m. **Program/Steering Committee Meeting
(Invitation Only)**
Castile 1

1:00 p.m. - 2:30 p.m. **Panel Sessions**

Racial and Ethnic Disparities in Mental Health and Clinical trials: What Can Be Done to Enhance Diversity and Eliminate Disparities?+	Depression, Attentional Bias and Emerging Role of Thyroid Function and Pharmacogenomic Testing in Mood Disorders	Exploring Potential Synergies Between Ketamine's Pharmacological Properties and Psychotherapeutic Treatment Approaches	*Real-World Evidence of Long-Term Ketamine/ Esketamine Therapy
<i>Princess Ballroom F</i>	<i>Princess Ballroom G</i>	<i>Princess Ballroom H</i>	<i>Princess Ballroom I</i>

2:30 p.m. - 2:45 p.m. **Break**
Princess East Foyer Desk

2:45 p.m. - 4:45 p.m. **Workshops**

Mid-Career Workshop: How to Advance your Career in the Hybrid/Remote Work Environment+	Controversies in Developing Psychedelic Treatment in Psychiatry	Early Career Workshop: Psychopharmacology "Prescribers' Workshop" for Trainees and Early Career Clinicians: The Design, Implementation, and Dissemination of a Model Curriculum
<i>Princess Ballroom F</i>	<i>Princess Ballroom G</i>	<i>Princess Ballroom H</i>

5:00 p.m. - 6:00 p.m. **ASCP Business Meeting and Reception
(ASCP Members Only)**
Princess Ballroom H

6:00 p.m. - 7:00 p.m. **ASCP Reception**
*La Hacienda Plaza and Trellis**

*Inclement Weather Backup is Salon A-E

***Of Special Interest To Clinicians +No CME Credits Offered**

FULL SCHEDULE

Wednesday, June 1, 2022

6:30 a.m. – 8:00 a.m. **Annual ASCP Fun Run/Walk – All Attendees Welcome (No Prior Sign Up Necessary)**
Palomino Conference Center North Drive

7:00 a.m. - 8:20 a.m. **Early Career Breakfast: How to Initiate Productive Collaborations with Industry, as well as Nonprofit Organizations While Appropriately Balancing Conflicts**
Princess Ballroom G

The Early Career Breakfast is an engaging opportunity to meet colleagues and learn how to collaborate with members of other institutions while balancing conflicts. The following presenters will share their experiences:

- Mahavir Agarwal, M.D., Ph.D., Centre for Addiction and Mental Health (CAMH)
- Leslie Citrome, M.D., M.P.H., New York Medical College
- Trisha Suppes, M.D., Ph.D., Stanford University
- Edward Nunes, M.D., NYSPI - Columbia University
- Joyce Tsai, Ph.D., COMPASS Pathways Ltd.

7:30 a.m. - 8:30 a.m. **NIA Breakfast Roundtable**
Castile 1

7:30 a.m. - 9:00 a.m. **Morning Break**
Princess East Foyer

7:30 a.m. - 6:00 p.m. **Speaker Ready Room**
Bourbon 11

7:30 a.m. - 7:00 p.m. **Registration**
Princess East Foyer Desk

8:30 a.m. - 10:00 a.m. **Regulatory Plenary: Psychedelic Drug Development: Perspectives from the FDA and EMA**
Salon A-E

Chair: Charles Grob, Harbor-UCLA Medical Center

Presenters: Tiffany Farchione, US Food and Drug Administration
 Maria Tome, European Medicines Agency
 Dominic Chiapperino, US Food and Drug Administration
 Cynthia LaCivita, US Food and Drug Administration
 Georgios Aislaitner, Federal Institute for Drugs and Medical Devices

This year's Regulatory Plenary will focus on psychedelic drug development. There is growing interest in the development of psychedelic drugs as potential treatments for psychiatric disorders. The psychoactive effects of psychedelic agents present considerations and challenges for the design, conduct, and interpretation of clinical trials. Representatives from both FDA and EMA will discuss their agencies' approaches to these development programs.

10:00 a.m. - 10:15 a.m. **Break**
Princess East Foyer

10:15 a.m. - 11:15 a.m. **ASCP Awards Ceremony and ASCP Lifetime Awardee Talk - Charles Reynolds, M.D.: Looking Back, Giving Thanks, and Moving Forward: Reflections on 50 Years as Physician/Scientist/Mentor in Geriatric Psychiatry**
Salon A-E

Chair: Madhukar Trivedi, University of Texas Southwestern Medical Center

Awards Presented to:

2022 Paul Wender Best Paper in *The Journal of Clinical Psychiatry* Award:

Brandon Nichter, Ph.D., U.S. Special Operations Command
 Nominated For: *Prevalence, Correlates, and Treatment of Suicidal Behavior in US Military Veterans: Results From the 2019-2020 National Health and Resilience in Veterans Study*

2022 Donald Klein Lifetime Achievement Award: Charles F. Reynolds III, M.D., University of Pittsburgh School of Medicine

This talk will provide a history of the award in addition to Dr. Reynolds' significant contributions to the field of Clinical Psychopharmacology.

***Of Special Interest To Clinicians +No CME Credits Offered**

11:15 a.m. - 1:00 p.m. **Poster Session I with Lunch+**
Palomino Ballroom 4-10
See pages 75-85 for a complete listing of posters

11:15 a.m. - 1:00 p.m. **Early Career Networking Tables**
(Open to all Attendees)
Palomino Ballroom 4-10

Panel Sessions

1:00 p.m. - 2:30 p.m. **Racial and Ethnic Disparities in Mental Health and Clinical Trials: What Can Be Done to Enhance Diversity and Eliminate Disparities?+**
Princess Ballroom F

Chair: Francisco Moreno, University of Arizona

Co-Chair: Inez Ruiz-White, Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC)

Discussant: Francisco Moreno, University of Arizona

1:00 p.m. – 1:10 p.m. **Introduction**

1:10 p.m. - 1:30 p.m. Luke Kramer, Evolution Research Group

1:30 p.m. - 1:50 p.m. John Kraus, Otsuka (OPDC)

1:50 p.m. - 2:10 p.m. Lionel Philips, Inside Edge Consulting Group

2:10 p.m. – 2:30 p.m. **Discussion**

1:00 p.m. - 2:30 p.m. **Depression, Attentional Bias and Emerging Role of Thyroid Function and Pharmacogenomic Testing in Mood Disorders**
Princess Ballroom G

Chair: Mark Frye, Mayo Clinic

Discussant: Randall Espinoza, UCLA

1:10 p.m. - 1:25 p.m. **Effects of Liothyronine (T3) in Neuronal Regeneration and Its Implications in Mood Disorders**
Mark Frye, Mayo Clinic

1:25 p.m. - 1:40 p.m. **Revisiting Treatment Implications of the Use of Thyroid Hormones in Mood Disorders**
Michael Gitlin, UCLA Medical Center

1:40 p.m. - 1:55 p.m. **The Relationship Between Free Triiodothyronine (FT3) and Emotional Processing in Bipolar Disorder**
Katherine Burdick, Brigham and Women's Hospital/
Harvard Medical School

1:55 p.m. - 2:10 p.m. **Deiodinase Variation and Liothyronine Treatment Interaction to Accelerate ECT Response in Major Depression: Pilot Data and Implications for Thyroid Pharmacogenomic Testing in Mood Disorders**
Nicolas Nunez, Mayo Clinic

2:10 p.m. - 2:30 p.m. **Discussion**

1:00 p.m. - 2:30 p.m. **Exploring Potential Synergies Between Ketamine's Pharmacological Properties and Psychotherapeutic Treatment Approaches**
Princess Ballroom H

Chair: Gerard Sanacora, Yale

Discussant: Sanjay J. Mathew, Baylor College of Medicine and Michael E. DeBakey VA Medical Center

1:10 p.m. - 1:30 p.m. **Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial**
Samuel Wilkinson, Yale School of Medicine

1:30 p.m. - 1:50 p.m. **A Brief, Fully Automated Neurocognitive Training Intervention Extends the Antidepressant Effect of a Single Ketamine Infusion**
Rebecca Price, University of Pittsburgh

1:50 p.m. - 2:10 p.m. **Mind, Interrupted: Harnessing the Effects of Ketamine in Addiction Treatment**
Elias Dakwar, College of Physicians and Surgeons
Columbia University

2:10 p.m. - 2:30 p.m. **Discussion**

1:00 p.m. - 2:30 p.m. ***Real-World Evidence of Long-Term Ketamine/Esketamine Therapy**
Princess Ballroom I

Chair: Balwinder Singh, Mayo Clinic

Discussant: Patricio Riva-Posse, Emory University School of Medicine

1:10 p.m. - 1:30 p.m. **Evidence of IV Ketamine for Treatment-Resistant Unipolar and Bipolar Depression and Observations from Running a Ketamine Clinic**
Jennifer Vande Voort, Mayo Clinic

1:30 p.m. - 1:50 p.m. **Efficacy and Safety of Ketamine/Esketamine Continuation for Treatment-Resistant Depression in Long-Term**
Balwinder Singh, Mayo Clinic

**Of Special Interest To Clinicians +No CME Credits Offered*

1:00 p.m. - 2:30 p.m.
(continued)

***Real-World Evidence of Long-Term Ketamine/
Esketamine Therapy**
Princess Ballroom I

1:50 p.m. - 2:10 p.m.

**Long-Term Outcomes and Considerations of
Intranasal Esketamine for Treatment Resistant
Depression - Is This Really the Miracle drug?**
Simon Kung, Mayo Clinic

2:10 p.m. - 2:30 p.m.

Discussion

2:30 p.m. - 2:45 p.m.

Break
Princess East Foyer Desk

Workshops

2:45 p.m. - 4:45 p.m.

**Mid Career Workshop: How to Advance Your
Career in the Hybrid/Remote Work Environment+**
Princess Ballroom F

Chair: Erika Saunders, Penn State College of Medicine, Penn State Health
Co-Chair: Ross Baker, VistaGen Therapeutics

Presenters: Carla Canuso, Janssen Research & Development
Kari Nations, Syneos Health
Michael Davis, US Food and Drug Administration

2:45 p.m. - 2:55 p.m.

Introduction

2:55 p.m. - 3:15 p.m.

**Advancing Your Career in the Hybrid/Remote
Work Environment: An Industry Perspective**
Carla Canuso, Janssen Research & Development

3:15 p.m. - 3:35 p.m.

**How to Advance Your Career in the Hybrid/
Remote Work Environment**
Kari Nations, Syneos Health

3:35 p.m. - 3:55 p.m.

**How to Advance Your Career in the Hybrid/
Remote Work Environment**
Michael Davis, US Food and Drug Administration

3:55 p.m. - 4:45 p.m.

Discussion

***Of Special Interest To Clinicians +No CME Credits Offered**

2:45 p.m. - 4:45 p.m. **Controversies in Developing Psychedelic Treatment in Psychiatry**
Princess Ballroom G

Chair: Trisha Suppes, Stanford University

Co-Chair: Scott Aaronson, Sheppard Pratt

Discussant: Mark Rapaport, University of Utah Huntsman Mental Health Institute

2:45 p.m. – 2:55 p.m. **Introduction**

2:55 p.m. – 3:15 p.m. **Improvement from Psychedelic Therapy is Different, How Do We Capture It?**
Scott Aaronson, Sheppard Pratt

3:15 p.m. – 3:35 p.m. **Psychedelic Therapist Training for Community Practice**
Elizabeth Nielson, Columbia University and New York State Psychiatric Institute

3:35 p.m. – 3:55 p.m. **Psychedelic Assisted Therapy for Depression: Unanswered Questions. Where? When? How Often?**
Tammy Miller, Sheppard Pratt

3:55 p.m. – 4:15 p.m. **Will Psychedelics Change Psychiatric Practice as We Know it?**
Trisha Suppes, Stanford University

4:15 p.m. – 4:45 p.m. **Discussion**

2:45 p.m. - 4:45 p.m.

**Early Career Workshop: Psychopharmacology
“Prescribers’ Workshop” for Trainees and Early
Career Clinicians: The Design, Implementation,
and Dissemination of a Model Curriculum**

Princess Ballroom H

Chair: Eileen Kavanagh, New York State Psychiatric Institute

Co-Chair: David Ross, University of Alberta

Discussant: Manish Jha, University of Texas Southwestern Medical Center

Presenters: Catherine Lowenthal, College of Physicians & Surgeons,
Columbia University
David Ross, University of Alberta

In this Early Career Committee workshop we will engage participants with an excerpt from our experiential, psychopharmacology “prescriber’s workshop”. We will then describe how the curriculum was adapted and customized for use at a second institution. At the second site, videos of expert faculty prescribing are an important part of the class. Finally, teaching faculty from both institutions will reflect on their experiences developing, adapting and implementing the curriculum, engaging participants in a discussion of how to optimize the value and accessibility of model curriculum resources.

This workshop is intended for faculty involved in core curriculum development and dissemination, particularly those interested in experiential learning techniques. It will require audience interaction and participation.

5:00 p.m. - 6:00 p.m.

**ASCP Business Meeting and Reception
(ASCP Members Only)**

Princess Ballroom H

6:00 p.m. - 7:00 p.m.

ASCP Reception

*La Hacienda Plaza and Trellis**

*Inclement Weather Backup is Salon A-E

AT-A-GLANCE

Thursday, June 2, 2022

7:15 a.m. - 8:15 a.m.	NIA Breakfast Roundtable <i>Castile 1</i>
7:30 a.m. - 9:00 a.m.	Morning Break <i>Princess East Foyer</i>
7:30 a.m. - 6:00 p.m.	Registration <i>Princess East Foyer Desk</i>
7:30 a.m. - 6:00 p.m.	Speaker Ready Room <i>Bourbon 11</i>
8:15 a.m. - 9:45 a.m.	Keynote Plenary: Reassessing Research and Clinical Practice in the Peri-pandemic Era <i>Salon A-E</i>
9:45 a.m. - 10:00 a.m.	Break <i>Princess East Foyer</i>
10:00 a.m. - 12:30 p.m.	Update From Federal and Other Funding Agencies <i>Salon A-E</i>
12:30 p.m. - 2:00 p.m.	Poster Session II with Lunch+ <i>Palomino Ballroom 4-10</i>
12:30 p.m. - 2:00 p.m.	Early Career Networking Tables (Open to all Attendees) <i>Palomino Ballroom 4-10</i>
2:00 p.m. - 3:30 p.m.	*Clinical Updates in Psychopharmacology <i>Salon A-E</i>
3:30 p.m. - 3:45 p.m.	Break <i>Princess East Foyer Desk</i>

Thursday

*Of Special Interest To Clinicians +No CME Credits Offered

3:45 p.m. - 5:15 p.m.

Panel Sessions

Achieving Diversity in Clinical Trials+	*Switch Versus Augmentation in Treatment-Resistant Depression: Literature and New Findings	Digital Measurement and Therapeutics in the Peri-Pandemic Era: Challenges and Opportunities+	An ASCP/AFSP Panel: Using Technology for Suicide Prevention
<i>Princess Ballroom F</i>	<i>Princess Ballroom G</i>	<i>Princess Ballroom H</i>	<i>Salon A-E</i>

*Of Special Interest To Clinicians +No CME Credits Offered

FULL SCHEDULE

THURSDAY, JUNE 2, 2022

7:15 a.m. - 8:15 a.m. **NIA Breakfast Roundtable**
Castile 1

7:30 a.m. - 9:00 a.m. **Morning Break**
Princess East Foyer

7:30 a.m. - 6:00 p.m. **Registration**
Princess East Foyer Desk

7:30 a.m. - 6:00 p.m. **Speaker Ready Room**
Bourbon 11

8:15 a.m. - 9:45 a.m. **Keynote Plenary: Reassessing Research and Clinical Practice in the Peri-pandemic Era**
Salon A-E

Chair: Mark Rapaport, University of Utah Huntsman Mental Health Institute

The COVID-19 pandemic has created a second pandemic of mental health and substance use disorders. The prevalence of anxiety and depression symptoms have increased in both adults and children. Problems with alcohol and substance use disorders have markedly increased. The intent of this plenary session is to begin to discuss how the COVID-19 is modifying our field. In particular we will investigate potential factors leading to the startling increase in mood disorders. Then we will discuss the short- and long-term neuropsychiatric aspects of infection with COVID-19. Our third presenter will describe how his team successfully developed a strategy and implemented a clinical trial of Fluvoxamine treatment for patients of COVID-19. Thus, this session will serve as a basis for further retirements of how:

1. The neuropsychiatric squali of COVID-19
2. How COVID-19 pandemic is changing psychiatric research

8:15 a.m. – 8:25 a.m. **Introduction**

8:25 a.m. – 8:40 a.m. **“This Sense of Being Abandoned”: COVID-19 and Mental Health**
Roy Perlis, Massachusetts General Hospital

8:15 a.m. - 9:45 a.m.
(continued)

Keynote Plenary: Reassessing Research and Clinical Practice in the Peri-pandemic Era
Salon A-E

8:40 a.m. – 8:55 a.m.

The Future of Clinical Trials is Remote: The Example of Fluvoxamine during COVID-19
Eric Lenze, Washington University School of Medicine

8:55 a.m. – 9:10 a.m.

Neuropsychiatric Sequelae of COVID-19
Scott Beach, Harvard Medical School, Massachusetts General Hospital

9:10 a.m. – 9:45 a.m.

Discussion

9:45 a.m. - 10:00 a.m.

Break
Princess East Foyer

10:00 a.m. - 12:30 p.m.

Update From Federal and Other Funding Agencies
Salon A-E

Chair: Leslie Citrome, New York Medical College

10:00 a.m. – 10:10 a.m.

Introduction

10:10 a.m. – 10:30 a.m.

The Latest in Drug Development from the NIMH
Josh Gordon, National Institute of Mental Health

10:30 a.m. – 10:50 a.m.

Alcohol Use Disorder: Closing the Treatment Gap
George Koob, National Institute on Alcohol Abuse and Alcoholism

10:50 a.m. – 11:10 a.m.

A 2022 Update on PCORI Research Priorities and Funding Opportunities in Mental Health
Holly Ramsawh, Patient-Centered Outcomes Research Institute

11:10 a.m. – 11:30 a.m.

Update of the Medications Development Program at NIDA
Ivan Montoya, National Institute on Drug Abuse

**Of Special Interest To Clinicians +No CME Credits Offered*

10:00 a.m. - 12:30 p.m. (continued)	Update From Federal and Other Funding Agencies <i>Salon A-E</i>
11:30 a.m. – 11:50 a.m.	An Update from Substance Abuse and Mental Health Services Administration Miriam Delphin-Rittmon, Substance Abuse and Mental Health Services Administration
11:50 a.m. – 12:10 p.m.	VA Office of Research & Development Research on Substance Use Disorders Jana Drgonova, Veteran's Administration
12:10 p.m. – 12:30 p.m.	Discussion
12:30 p.m. - 2:00 p.m.	Poster Session II+ <i>Palomino Ballroom 4-10</i> <i>See pages 86-95 for a complete listing of posters</i>
12:30 p.m. - 2:00 p.m.	Early Career Networking Tables (Open to all Attendees) <i>Palomino Ballroom 4-10</i>
2:00 p.m. - 3:30 p.m.	*Clinical Updates in Psychopharmacology <i>Salon A-E</i>

Chair: Erika Saunders, Penn State College of Medicine

This session will feature three leading psychopharmacologists in reviewing the treatment of insomnia, psychosis and mood disorders.

2:00 p.m. – 2:10 p.m.	Introduction
2:10 p.m. – 2:30 p.m.	Update on Insomnia Pharmacotherapy Andrew Krystal, University of California, San Francisco
2:30 p.m. – 2:50 p.m.	Psychosis Update Oliver Freudenreich, Massachusetts General Hospital

2:00 p.m. - 3:30 p.m.
(continued)

***Clinical Updates in Psychopharmacology**
Salon A-E

2:50 p.m. – 3:10 p.m.

**Making the Most with What We Have to Offer:
Combined and Sequential Therapies for Patients
with Difficult to Treat Mood Disorders**

Michael E. Thase, Perelman School of Medicine,
University of Pennsylvania, and Corporal Michael J.
Crescenzo VAMC

3:10 p.m. – 3:30 p.m.

Discussion

3:30 p.m. - 3:45 p.m.

Break

Princess East Foyer Desk

Panel Sessions

3:45 p.m. – 5:15 p.m.

Achieving Diversity in Clinical Trials+
Princess Ballroom F

Chair: Shishuka Malhotra, Neuro Behavioral Clinical Research

Discussant: Shishuka Malhotra, Neuro Behavioral Clinical Research

3:45 p.m. – 3:55 p.m.

Introduction

3:55 p.m. – 4:15 p.m.

**Practical Implementation of DE and I in Clinical
Trials**

Alexandria Wise, Syneos Health

4:15 p.m. – 4:35 p.m.

**Diversity, Equity and Inclusion: Globalized
Insights for Localized Strategies**

Charles Wilcox, Praxis Research Consulting

4:35 p.m. – 4:55 p.m.

**Operationalizing the Enhancement of Diversity in
Clinical Trials**

Stacey Versavel, Cerevel Therapeutics

4:55 p.m. – 5:15 p.m.

Discussion

3:45 p.m. – 5:15 p.m.

***Switch Versus Augmentation in Treatment-Resistant Depression: Literature and New Findings**

Princess Ballroom G

Chair: George Papakostas, Massachusetts General Hospital

Discussant: Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenzo VAMC

3:45 p.m. – 3:55 p.m.

Introduction

3:55 p.m. – 4:10 p.m.

Switching Antidepressants as a Strategy in Resistant Depression

Maurizio Fava, Massachusetts General Hospital

4:10 p.m. – 4:25 p.m.

Augmentation Versus Switch: Results of the PCORI-Funded Ascertain-TRD Trial

George Papakostas, Massachusetts General Hospital

4:25 p.m. – 4:40 p.m.

Augmentation Vs. Switching Antidepressants for Treatment Resistant Depression in Older Adults: What Provides the Most Benefits? What is Safest? Results from the Optimum Clinical Trial

Eric Lenze, Washington University School of Medicine

4:40 p.m. – 4:55 p.m.

Comparative Effectiveness of Electroconvulsive Therapy vs. Intravenous Ketamine for Treatment Resistant Depression (ELEKT-D) Trial: Update on Design and Implementation

Amit Anand, MGH Brigham, Harvard Medical School

4:55 p.m. – 5:15 p.m.

Discussion

3:45 p.m. – 5:15 p.m.**Digital Measurement and Therapeutics in the Peri-Pandemic Era: Challenges and Opportunities+***Princess Ballroom H***Chair:** Timothy Mariano, Woebot Health; Brown Medical School; Providence VAMC**Discussant:** Justin Baker, Harvard Medical School McLean Hospital**3:45 p.m. – 3:55 p.m.****Introduction****3:55 p.m. – 4:10 p.m.****No Looking Back: Tech-Enabling the Practice of Psychiatry**

Cynthia Epperson, University of Colorado Anschutz Medical Campus

4:10 p.m. – 4:25 p.m.**Digital Biomarkers and Their Application in Everyday Mental Health Care**

Georgia Mitsi, Biogen

4:25 p.m. – 4:40 p.m.**Developing, Testing, and Taking a Digital Intervention for Depression to FDA Indication: Challenges and Opportunities**

Ellen Frank, University of Pittsburgh School of Medicine

4:40 p.m. – 4:55 p.m.**Software as a Medical Device for Treatment of Mental Health Conditions: Promise and Challenge**

Alison Darcy, Woebot Health

4:55 p.m. – 5:15 p.m.**Discussion**

3:45 p.m. – 5:15 p.m.

**An ASCP/AFSP Panel: Using Technology for
Suicide Prevention**

Salon A-E

Chair: Jill Harkavy-Friedman, American Foundation for Suicide Prevention

Co-Chair: Madhukar Trivedi, University of Texas Southwestern Medical Center

3:45 p.m. – 3:55 p.m.

Introduction

3:55 p.m. – 4:15 p.m.

**Using New Technology to Improve the Prediction
and Prevention of Suicidal Behavior**

Matthew Nock, Harvard University

4:15 p.m. – 4:35 p.m.

**Challenges and Opportunities for Text-Based
Crisis Response - Lessons Learned in 2020 with
SafeUT**

Scott Langenecker, University of Utah

4:35 p.m. – 4:55 p.m.

**Technology as a Tool and Outcome in Clinical
Trials**

Jill Harkavy-Friedman, American Foundation for
Suicide Prevention

4:55 p.m. – 5:15 p.m.

Discussion

[illegible]

AT-A-GLANCE

Friday, June 3, 2022

- 7:30 a.m. - 9:00 a.m. **Morning Break**
Princess East Foyer
- 7:30 a.m. - 10:30 a.m. **Speaker Ready Room**
Bourbon 11
- 7:30 a.m. - 12:00 p.m. **Registration**
Princess East Foyer Desk
- 8:30 a.m. - 10:00 a.m. **Panel Sessions**

*Augmenting Vs. Switching Antidepressant for Treatment Resistant Depression in Older Adults: Results from the Optimum Study <i>Princess Ballroom F</i>	*Challenges and Opportunities in the Use of Real-World Evidence to Advance Treatment Development in Behavioral Health+ <i>Princess Ballroom G</i>	Neurophysiological Biomarkers in the Context of Early Phase Clinical Trials for Major Depressive Disorder <i>Salon A-E</i>
---	---	---

- 10:00 a.m. - 10:15 a.m. **Break**
Princess East Foyer
- 10:15 a.m. - 11:45 a.m. **Regulatory Wrap-Up Plenary**
Salon A-E
- 12:00 p.m. **Meeting Adjourns**

[illegible]

FULL SCHEDULE

FRIDAY, JUNE 3, 2022

- 7:30 a.m. - 9:00 a.m. Morning Break**
Princess East Foyer
- 7:30 a.m. - 10:30 a.m. Speaker Ready Room**
Bourbon 11
- 7:30 a.m. - 12:00 p.m. Registration**
Princess East Foyer Desk

Panel Sessions

- 8:30 a.m. - 10:00 a.m. *Augmenting Vs. Switching Antidepressant for Treatment Resistant Depression in Older Adults: Results from the Optimum Study**
Princess Ballroom F

Chair: Helen Lavretsky, David Geffen School of Medicine at UCLA
Discussant: Charles Reynolds, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic

- 8:30 a.m. – 8:40 a.m. Introduction**
- 8:40 a.m. - 9:00 a.m. Pragmatism, Context, and Lessons Learned: Planning for Impactful Dissemination**
Jordan Karp, University of Arizona
- 9:00 a.m. - 9:20 a.m. What Treatment Choices are Effective? Safe? Futile? Results from the Optimum Study**
Eric Lenze, Washington University School of Medicine
- 9:20 a.m. - 9:40 a.m. Optimizing Outcomes of Treatment-Resistant Depression (TRD) in Older Adults (OPTIMUM): Effects on Psychological Well-Being**
Helen Lavretsky, David Geffen School of Medicine at UCLA
- 9:40 a.m. – 10:00 a.m. Discussion**

8:30 a.m. – 10:00 a.m.

***Challenges and Opportunities in the Use of Real-World Evidence to Advance Treatment Development in Behavioral Health+**
Princess Ballroom G

Chair: Scott Kollins, Holmusk

Discussant: Tiffany Farchione, US Food and Drug Administration

8:30 a.m. – 8:40 a.m.

Introduction

8:40 a.m. – 9:00 a.m.

Real-World Evidence Data in Pharmaceutical Products R and D from Registration to Reimbursement: Challenges and Opportunities
Luca Pani, University of Miami

9:00 a.m. – 9:20 a.m.

Industry Perspective on Rwe for Behavioral Health
Shuvayu Sen, Otsuka Pharmaceutical Companies

9:20 a.m. – 9:40 a.m.

Using Real World Data to Generate High Quality Real World Evidence: Lessons Learned from Ophthalmology
Durga Borkar, Duke University Eye Center

9:40 a.m. – 10:00 a.m.

Discussion

8:30 a.m. - 10:00 a.m. **Neurophysiological Biomarkers in the Context of Early Phase Clinical Trials for Major Depressive Disorder**
Salon A-E

Chair: Nicholas Murphy, Baylor College of Medicine

Co-Chair: Sanjay J. Mathew, Baylor College of Medicine and Michael E. DeBakey VA Medical Center

Discussant: Carlos Zarate, National Institute of Mental Health

8:30 a.m. – 8:40 a.m. **Introduction**

8:40 a.m. - 9:00 a.m. **Applying Neurophysiological Biomarkers to Clinical Trials of NMDA Receptor Modulation for the Treatment of Mood and Trauma Disorders**
Nicholas Murphy, Baylor College of Medicine

9:00 a.m. - 9:20 a.m. **TMS-EEG Indices as High Potential Predictive Markers of Brain Stimulation Response in Major Depressive Disorder**
Daphne Voineskos, University of Toronto

9:20 a.m. - 9:40 a.m. **Electrophysiological Biomarkers of Ketamine Response in Treatment-Resistant Major Depression**
Jessica Gilbert, National Institute of Mental Health

10:00 a.m. - 10:15 a.m. **Break**
Princess East Foyer

10:15 a.m. - 11:45 a.m. **Regulatory Wrap-Up Plenary**
Salon A-E

Chair: Trisha Suppes, Stanford University

Speakers: Maria Tome, European Medicines Agency
Tiffany Farchione, US Food and Drug Administration
Bernard Fischer, U.S. Food and Drug Administration
Marion Haberkamp, Federal Institute of Drugs and Medical Devices

12:00 p.m. **Meeting Adjourns**

Biomarkers of Response to Ketamine in Treatment-Resistant Depression

Chair: Mark Frye, Mayo Clinic

Discussant: Mark Frye, Mayo Clinic

Introduction

A Single-Arm, Open-Label Study of Biomarkers of Remission with IV Ketamine for Non-Psychotic Unipolar or Bipolar Treatment-Refractory Depression: Clinical Outcomes

Sagar Parikh, University of Michigan, Ann Arbor

Metabolomics Informs About Rapid Mechanism of Action of Ketamine and Varied Response to Treatment

Rima Kaddurah-Daouk, Duke University School of Medicine

Central Biomarkers of Ketamine Response

Balwinder Singh, Mayo Clinic

*Metabolic Health in Severe Mental Illness: Novel Intervention Strategies Toward Reducing the Mortality Gap

Chair: Margaret Hahn, Centre for Addiction and Mental Health

Co-Chair: Cynthia Calkin, Dalhousie University Faculty of Medicine

Discussant: Christoph Correll, The Zucker Hillside Hospital

Introduction

Preventing Antipsychotic Induced Weight Gain – an RCT of Metformin to Ameliorate Weight Gain with Clozapine

Dan Siskind, The University of Queensland

Metformin for the Prevention of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis, and a Retrospective Chart Review

Mahavir Agarwal, Centre for Addiction and Mental Health

Treating insulin Resistance to Improve Outcomes in Bipolar Disorder (TRIO-BD) Study Results Suggest Underlying Mechanism of Treatment Resistant Bipolar Depression

Cynthia Calkin, Dalhousie University Faculty of Medicine

International External Validation and Revision in Two Countries of the Psymetric Cardiometabolic Risk Prediction Algorithm for Young People with Psychosis

Benjamin Perry, University of Cambridge

**Of Special Interest To Clinicians +No CME Credits Offered*

Wednesday, June 1, 2022

11:15 a.m. - 1:00 p.m.

Poster Session I with Lunch

Palomino Ballroom 4-10

W1. Extrapolation of Efficacy of a Dextroamphetamine Transdermal System from Pediatric to Adult Populations Using Pharmacokinetic Modeling

Mariacristina Castelli, Noven Pharmaceuticals, Inc.

Mariacristina Castelli*, Katsumi Suzuki, Brittney Starling, Kanan Balakrishnan, Suzanne Meeves, Marina Komaroff, Janelle Lennie, John T. Mondick, Stephen V. Faraone

W2. Single Cell Transcriptomics Reveals Distinct Transcriptional Response to Oxycodone and Buprenorphine by Ipsc-Derived Brain Organoids from Patients with Opioid Use Disorder

Ming-Fen Ho, Mayo Clinic

Ming-Fen Ho*, Cheng Zhang, Irene Moon, Brandon Coombes, Joanna Biernacka, Michelle Skime, Tyler Oesterle, Victor Karpyak, Kristen Schmidt, Kate Gliske, Quyen Ngo, Cedric Skillon, Marvin Seppala, Hu Li, Richard Weinshilboum

W3. Comparative Effectiveness of Buprenorphine and Naltrexone in Opioid Use Disorder and Co-Occurring Polysubstance Use: A Case-Crossover Analysis

Kevin Xu, Washington University in St. Louis

Kevin Xu*, Carrie Mintz, Ned Presnall, Laura Bierut, Richard Grucza

W4. Transcranial Focused Ultrasound Can Attenuate Anxiety in Healthy Volunteers

Norman Spivak, David Geffen School of Medicine at UCLA

Norman Spivak*, Bianca Dang, Andrew Swenson, Sabrina Halavi, Sergio Becerra, Luka Cvijanovic, Sonja Hiller, Nanthia Suthana, Martin Monti, Taylor Kuhn, Susan Bookheimer

W5. Genetic Polymorphisms and Clinical Implications of the Use of Stimulants Agents in Adults with Mood and Attentional Deficits Disorders: A Systematic Review

Alfredo Cuellar-Barboza, Universidad Autonoma de Nuevo Leon



Nicolas Nunez, Sofia Jezzini, Balwinder Singh, Manuel Gardea Resendez, Boney Joseph, Mark Frye, Alfredo Cuellar-Barboza*



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

-  **W6. Central Cortisol Alone is Differentially Regulated as a Function of Age but Not Cognitive Impairment in Simultaneous Basal Measurements of Human Cerebrospinal Fluid, Saliva, and Total and Free Plasma Cortisol**
Katharine Liang, VA Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System
Katharine Liang*, Elizabeth Colasurdo, Ge Li, Jane Schofer, Elaine Peskind
-  **W7. Exploring Genetic Variation of Complex I as Potential Marker of Increased Mitochondrial Function Associated with Antidepressant-Induced Mania.**
Manuel Gardea Resendez, Mayo Clinic
Manuel Gardea Resendez*, Brandon Coombes, Marin Veldic, Sussanah Tye, Alfredo Cuellar-Barboza, Francisco Romo- Nava, Ana Andreazza, Balwinder Singh, Nicolas Nunez, Miguel Prieto, Aysegul Ozerdem, Joanna Biernacka, Susan McElroy, Tamas Kozicz, Mark Frye
- W8. Metabolic Syndrome in Bipolar Depression with Lumateperone (ITI-007): A Post Hoc Analysis of 2 Randomized, Placebo-Controlled Trials**
Suresh Durgam, Intra-Cellular Therapies, Inc.
Christoph U. Correll, Suresh Durgam*, Susan G. Kozauer, Jason Huo, Robert E. Davis, Sharon Mates
- W9. Efficacy of Aripiprazole Once-Monthly for the Maintenance Treatment of Patients with Bipolar I Disorder: A Post-Hoc Analysis by Age**
Jessica McDonough, Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC)
Pedro Such, Jessica Madera-McDonough, Maxine Chen, Heather Fitzgerald, Murat Yildirim, Jessica McDonough*
- W10. Efficacy and Safety of Brexiprazole for the Treatment of Borderline Personality Disorder: A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study**
Brian Rothman, Otsuka Pharmaceutical Development and Commercialization Inc.
Brian Rothman*, Claudette Brewer, Denise Chang, Mary Hobart, Nanco Hefting, Robert D. McQuade, Jon Grant



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

W11. Reconnect (ZYN2-CL-033): Design of a Phase 3 Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome Based Upon Learnings from Connect-Fx (ZYN2-CL-016) Completed During SARS-COV-2 Pandemic

Stephen O'Quinn, Zynerva Pharmaceuticals

Nancy Tich, Terri Sebree, Thomas Dobbins, Elizabeth Merikle, Chris Brady, Stephen O'Quinn*

W12. Combining Pharmacotherapy of BI 425809 with Computerized Cognitive Training in Patients with Schizophrenia: Baseline Data and Patient Demographics from an Ongoing Phase II Trial

Glen Wunderlich, Boehringer Ingelheim

Glen Wunderlich*, Sean McDonald, Eric Fu, Philip D. Harvey

W13. Could Sudden Discontinuation of Suboxone Induce Mania and Psychosis?

Yezhe Lin, Virginia Tech Carilion School of Medicine

Alexander Zhang, Ching-Fang Sun, Justin White, Anita Kablinger, Rachel Martin, Yezhe Lin*

W14. New Edition: A Model Psychopharmacology Curriculum for Teachers of Psychiatric Residents

Ira Glick, Stanford University School of Medicine

Ira Glick*

W15. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: Results of a Randomized Phase 3 Placebo-Controlled Study (Study 302)

Paul Yeung, AbbVie

Robert Riesenberger, Paul Yeung*, Ludmyla Reveda, Gary S. Sachs, Majid Kerolous, Willie R. Earley, Maurizio Fava

W16. Improvement in Clinical Global Impression Scores with Zuranolone in Patients with Major Depressive Disorder: Results from the LANDSCAPE Clinical Development Program

Anita H. Clayton, University of Virginia

Anita H. Clayton*, Robert Lasser, Indrani Nandy, Colville Brown, Divya Narayanan, Mona Kotecha, Fiona Forrestal, James Doherty, Andrew Cutler



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W17. Use of Nonparametric Testing and Bayesian Analyses to Analyze Major Depressive Disorder Clinical Trial Results: Post-Hoc Sensitivity Analyses of Two Phase 3 Cariprazine Studies

Ludmyla Rekeda, AbbVie Pharmaceutical

Ludmyla Rekeda*, Xiaotian Chen, Hongjian Zhu, Majid Kerolous, Ken Kramer, Paul Yeung, Julie Adams

W18. Estimating Changes in Weight and Metabolic Parameters Before and After Treatment with Cariprazine: A Retrospective Study of Electronic Health Records

Andrew Cutler, SUNY Upstate Medical University

Prakash Masand, Roger McIntyre, Andrew Cutler*, Kiren Patel, Ken Kramer, Amanda Harrington, Huy-Binh Nguyen

W19. Zuranolone Safety and Efficacy in Patients with Major Depressive Disorder (MDD): Interim 50 mg Cohort Response and Remission Outcomes From the Open-Label, Phase 3, SHORELINE Study

Andrew Cutler, SUNY Upstate Medical University

Andrew Cutler*, Gregory Mattingly, Scott Aaronson, Robert Lasser, Indrani Nandy, Nilanjana Rana, Colville Brown, Catherine Miller, Mona Kotecha, Fiona Forrestal, James Doherty

W20. Head-To-Head Comparison of Vortioxetine Vs Desvenlafaxine in Patients with Major Depressive Disorder with Partial Response to Selective Serotonin Reuptake Inhibitors: Preliminary Baseline Data from the Vivre Study

Michael Cronquist Christensen, H. Lundbeck A/S

Roger McIntyre, Simon Nitschky Schmidt, Michael Cronquist Christensen*

W21. A Multicentre, International Phase IIb Randomised Controlled Trial of COMP360 Psilocybin Therapy in Treatment-Resistant depression: Response and Remission Rates

Joyce Tsai, COMPASS Pathways Ltd.

Guy Goodwin, Scott Aaronson, Boadie W. Dunlop, David Feifel, David Hellerstein, Lindsey Marwood, Sunil Mistry, Metten Somers, Susan Stansfield, Joyce Tsai*, Samuel Williams, Allan H. Young, Sid Zisook, Ekaterina Malievskaia

W22. Factors Associated with Patient Activation Among Individuals with Depression within Race/Ethnic Groups

Jacqueline Pesa, Janssen Scientific Affairs, LLC

Janelle Cambron-Mellott, Jacqueline Pesa*, Muideen Adigun, Nate Way, H. Jean Wright



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W23. Seltorexant Reduces Core Depressive Symptoms in Patients with Major Depressive Disorder: Analysis Based on MADRS-WOSI and MADRS-6

Michael E. Thase, Perelman School of Medicine, University of Pennsylvania, and Corporal Michael J. Crescenzo VAMC
Michael E. Thase*, Ewa Wajs, Yun Zhang, Haiyan Xu, Mila Etropolski, Gahan Pandina, Patricia Cabrera, Wayne C. Drevets

W24. A Multicentre, International Phase IIb Randomised Controlled Trial of COMP360 Psilocybin Therapy in Treatment-Resistant Depression: Changes in Affect, Anxiety and Further Exploratory Endpoints

Lindsey Marwood, COMPASS Pathways Ltd.
Guy Goodwin, Scott Aaronson, Boadie W. Dunlop, David Feifel, David Hellerstein, Lindsey Marwood*, Sunil Mistry, Metten Somers, Susan Stansfield, Joyce Tsai, Samuel Williams, Allan H. Young, Sid Zisook, Ekaterina Malievskaia

W25. Characteristics and Real-World Treatment Patterns of Adults with Treatment Resistant Depression Completing Esketamine Induction Treatment Per Drug Label in United States

Kruti Joshi, Janssen Scientific Affairs, LLC
Maryia Zhdanava, Swapna Karkare, Dominic Pilon, Aditi Shah, Christopher Holiday, Kruti Joshi*

W26. Real-World Treatment Patterns, Healthcare Resource Use, and Costs of Patients with Treatment Resistant Depression and a History of Comorbid Cardiovascular or Metabolic Condition Initiating Esketamine in United States

Kruti Joshi, Janssen Scientific Affairs, LLC
Swapna Karkare, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Christopher Holiday, Kruti Joshi*

W27. Concurrent PTSD and the Management of Depressive Disorders in Primary Care Clinics Utilizing a Psychopharmacological Care Management Program

Zachary Zuschlag, James A. Haley Veterans Hospital
Zachary Zuschlag*, Benjamin Lord, Kaitlin Leonard, Vanessa Milsom



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W28. Auricular Transcutaneous Hi-Frequency E-Mmunotherapy Sequences (ATHENS) for Major Depressive Disorder (MDD) with Peripartum Onset with and without Concomitant Antidepressant Use: A Multicenter, Open-Label Pilot Study

Kristina Deligiannidis, Zucker Hillside Hospital

Kristina Deligiannidis*, Thalia Robakis, Sarah Homitsky, Erona Ibroci, Bridget King, Diana Coppola, Sunu Jacob, Shane Raines, Konstantinos Alataris

W29. COVID-19 Vaccination Status in the Major Depressive Disorder Clinical Trial-Seeking Population

Jenicka Engler, Adams Clinical

Jenicka Engler*, Miriam Evans, Sarah Starling, Dennis Fagundo, Koo Grace, Hasiba Zandi, Grace Moore, Steven Harber, Sarah Nicholas, Alyssa Quicquaro, Dyanna Domilici, Daniel Thorpe

W30. Sunshine Increased Placebo Effect in Antidepressant Studies: A New Ground to Break

Joël Gailliedreau, Private CIC Ambroise Pare

Joël Gailliedreau *, Béatrice Gailliedreau

W31. Results from a Study of Self-reported Experiences Associated with Sleep Onset with Lemborexant vs Zolpidem

Margaret Moline, Eisai Inc.

C. Brendan Montano, Manoj Malhotra, Dinesh Kumar, Carlos Perdomo, Margaret Moline*

W32. The Effect of Lemborexant on Apnea-hypopnea Index and Peripheral Oxygen Saturation in Adult and Elderly Subjects with Moderate or Severe Obstructive Sleep Apnea

Jocelyn Cheng, Eisai Inc.

Margaret Moline, Jocelyn Cheng*, Daniel Lorch, Nancy Hall, Dhara Shah

W33. Social Determinants of Health, Healthcare Resource Utilization, and Costs Among Patients with Major Depressive or Bipolar I Disorder by Payer Type

Dusica Hadzi Boskovic, Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC)

Christie Teigland, Seung Kim, Iman Mohammadi, Barnabie Agatep, Dusica Hadzi Boskovic*



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

W34. A Real-World Comparison of Patients Prescribed Aripiprazole Tablet with Sensor and Patients Prescribed Aripiprazole Alone in the US

Dusica Hadzi Boskovic, Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC)

Dusica Hadzi Boskovic*, Magdaliz Gorritz, Marie Yasuda, Jing He, Chi-Chang Chen

W35. Prevalence of Psychiatric Disorders and Use of Psychotropic Medications in Patients who Underwent Pharmacogenomics Testing: Findings from a Very Large Sample and “Big Data” Analysis

Yuliang Hu, Mayo Clinic

Yuliang Hu*, Simon Kung

W36. Early Stabilization of Weight Changes Following Treatment with Olanzapine, Risperidone and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis

Sally Mustafa, Douglas Mental Health Research Institute

Sally Mustafa*, Ridha Joober, Srividya Iyer, Jai Shah, Martin Lepage, Ashok Malla

W37. Opioid Prescription Dispensing Patterns Among Patients with Schizophrenia or Bipolar Disorder

Brittany Roy, Alkermes, Inc.

Brittany Roy*, Jianheng Li, Cathy Lally, Sarah C. Akerman, Maria A. Sullivan, James Fratanonio, William Dana Flanders, Made Wenten

W38. Patient Versus Caregiver and Clinician Reports of Cognitive Difficulties in Patients with Schizophrenia Switching to Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: A Post Hoc Analysis

James McGrory, Alkermes, Inc.

Mark G. A. Opler, Amy Claxton, James McGrory*, Sabina Gasper, Meihua Wang, Sergey Yagoda

W39. Synergy Between VMAT2 Inhibitors and Antipsychotics in Animal Models of Schizophrenia

Ryan Terry-Lorenzo, Neurocrine Biosciences, Inc.

Sam R. J. Hoare, Andrea Kudwa, Ryan Terry-Lorenzo*, Dimitri E. Grigoriadis



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W40. Acetylcholine as a Regulator of Dopamine Pathways Implicated in Psychosis: Rationale for Selective Muscarinic Receptor Agonists as Candidates for Treatment of Schizophrenia

Peter Weiden, Karuna Therapeutics

Peter Weiden*, Samantha E. Yohn, Christian C. Felder

W41. A Single-Day, Two-Injection Start Regimen for Aripiprazole Once-Monthly in Patients With Schizophrenia or Bipolar I Disorder Who Have Been Stabilized on Oral Aripiprazole

Pedro Such, H. Lundbeck A/S

Pedro Such*, Jessica Madera-McDonough, Matt Harlin, Frank Larsen, Murat Yildirim

W42. Modeling Reaction Time Distributions Increases the Statistical Power of Cognition Testing

Seth C. Hopkins, Sunovion Pharmaceuticals, Inc.

Seth C. Hopkins*, Sean D. Wilson, Ajay Ogirala, Gabriel Stellman,

Snezana Milanovic, Steven T. Szabo, James A. Rogers, Kenneth Koblan

W43. Healthcare Resource Use Decreases Following Initiation of Aripiprazole 400mg Long-Acting Injectable: A Real-World Electronic Health Record Database Study

Heidi Waters, Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC)

Heidi Waters*, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran

Thadani, Miguel E. Rentería, Subina Surendran, A. John Rush, Joydeep Sarkar, Maxine Chen, Heather Fitzgerald, Xue Han



W44. Hippocampal Blood-brain Barrier and Peripheral Endothelial Dysfunction in Schizophrenia Pathophysiology as a Putative Vascular Disease Mechanism

Eric Goldwaser, University of Maryland / Sheppard Pratt

Eric Goldwaser*, Randel Swanson, Wyatt Marshall, Alexa Yuen, Robert Nagele, Elliot Hong, Nimish Acharya



W45. The Mind After Midnight: Nocturnal Wakefulness Increases Risk of Death by Suicide and Homicide

Andrew Tubbs, University of Arizona College of Medicine

Andrew Tubbs*, Fabian-Xosé Fernandez, Jordan Karp, Michael Perlis, Michael Grandner



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W46. Pregnancy Outcomes After First Trimester Exposure to Buspirone: Prospective Longitudinal Outcomes from the MGH National Pregnancy Registry for Psychiatric Medications

Marlene Freeman, Massachusetts General Hospital, Ammon-Pinizzotto Center for Women's Mental Health

Marlene Freeman*, Mercedes Szpunar, Lauren Kobylski, Adele Viguera, Lee Cohen

W47. Zuranolone Safety and Efficacy in Patients with Major Depressive Disorder (MDD) and Metabolic Comorbidities: Results from the Phase 3 SHORELINE Study

Scott Aaronson, Sheppard Pratt

Gregory Mattingly, Scott Aaronson*, Robert Lasser, Indrani Nandy, Nilanjana Rana, Colville Brown, Divya Narayanan, Richard Hughes, James Doherty, Andrew Cutler

*** W48. Efficacy and Safety of Zuranolone Co-Initiated with an Antidepressant in Adults with Major Depressive Disorder: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled Coral Study**

Scott Aaronson, Sheppard Pratt

Sagar Parikh, Scott Aaronson*, Sanjay Mathew, Gustavo Alva, Charles Debattista, Robert Lasser, Amy Bullock, Mona Kotecha, JungAh Jung, Fiona Forrestal, Manny Garcia, Divya Narayanan, James Doherty

*** W49. Luvadaxistat, an Investigational D-Amino Acid Oxidase Inhibitor, was Associated with Signals of Efficacy in Cognitive Impairment Associated with Schizophrenia but Not Negative Symptoms: Results from the Interact Study**

Jaskaran Singh, Neurocrine Biosciences

Jaskaran Singh*, Venkatesha Murthy, Elizabeth Hanson, Nicholas Demartinis, Mahnaz Asgharnejad, Cheng Dong, Rebecca Evans, Tingting Ge, Eduardo Dunayevich, Emiliangelo Ratti, Silvana Galderisi

*** W50. Darigabat Reduces Acute Panic and Fear Symptoms Induced by CO2 Inhalation in Healthy Participants**

Rachel Gurrell, Cerevel Therapeutics

Rachel Gurrell*, Ih Chang, Ann Dandurand, Sridhar Duvvuri, Amy Giugliano, Gina Pastino, Theresa Pham, Stacey Versavel, Gabriel Jacobs, Koshar Safai Pour, Rob Zuiker, Raymond Sacher, John Renger



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

*** W51. MK-8189, a Novel PDE10A Inhibitor for the Treatment of Schizophrenia**

Michael Egan, Merck and Co., Inc.

Michael Egan*

W52. Treatment Patterns and Economic Burden Associated with First Versus Subsequent Adjunctive Atypical Antipsychotic Use in Patients with Major Depressive Disorder

Amanda Harrington, AbbVie

Rakesh Jain, Sara Higa, François Laliberté, Guillaume Germain, Malena

Mahendran, Mousam Parikh, Amanda Harrington*

W53. Real-World Prediction and Estimated Prevalence of Bipolar I Disorder Misdiagnosis Among Patients with Major Depressive Disorder

Amanda Harrington, AbbVie

Roger McIntyre, François Laliberté, Guillaume Germain, Sean

MacKnight, Amanda Harrington*

W54. The Effect of Lurasidone on Anhedonia in Adult Patients with Bipolar Depression

Michael Tocco, Sunovion Pharmaceuticals, Inc.

Roger McIntyre, Andrei Pikalov, Yongcai Mao, Michael Tocco*

W55. Hostile Interpretation Bias and Avoidance Related to Concern for Risk of Violence towards Others in a PTSD Pharmacotherapy Treatment Trial

Rebecca Hendrickson, VA Puget Sound Health Care System

Rebecca Hendrickson*, Milli Wijenaik-Bogle, Sophia Robinson

W56. AXS-05 (Dextromethorphan-Bupropion) Improves Depressive Symptoms and Functioning in Patients with One Prior Treatment Failure: Results from the EVOLVE Long-Term, Open-Label Study

Amanda Jones, Axsome Therapeutics

Amanda Jones*, Caroline Streicher, Zachariah Thomas, Herriot

Tabuteau

W57. Improvement in Anxiety Symptoms in Depressed Patients Treated with AXS-05 (Dextromethorphan-Bupropion): Results from the EVOLVE Open-label, Long-term Study

Amanda Jones, Axsome Therapeutics

Amanda Jones*, Caroline Streicher, Zachariah Thomas, Herriot

Tabuteau



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

W58. A Pilot Study of Low-Intensity Focused Ultrasound for Treatment-Resistant Generalized Anxiety Disorder

Elisabeth Rindner, The Regenes Project

Elisabeth Rindner*, Kennedy Mahdavi, Margaret Zielinski, Jonathan Haroon, Kaya Jordan, Barshen Habelhah, Segio Becerra, Alexander Bystritsky, Taylor Kuhn, Sheldon Jordan

W59. Updated Treatment of Dementia with Bosutinib: An Open-Label Study of a Tyrosine Kinase Inhibitor

Margaret Zielinski, Neurological Associates - The Interventional Group

Margaret Zielinski*, Kennedy Mahdavi, Hannah Barrows, Barshen Habelhah, Marisa Chang, Santosh Kesari, Alexander Bystritsky, Ed O'Connor, Hyman Gross, Scott Pereles, Mike Whitney, Taylor Kuhn, Sheldon Jordan

W60. Identifying Patients with High Burden of Positive and Negative Schizophrenia Symptoms in Electronic Health Record Data Using Natural Language Processing

Rashmi Patel, Holmusk

Rashmi Patel*, Emily Palmer, Rifqi Alkhatib, Yida Won, Soon Nan Wee, Simran Thadani, Lu Wang, Miguel E. Rentería

W61. ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson's Disease Psychosis: Analysis of Medicare Beneficiaries

Nazia Rashid, ACADIA Pharmaceuticals Inc

Shikhar Kumar, Nazia Rashid*, Dilesh Doshi, Krithika Rajagopalan

W62. The Use of Digital Health Technologies in Mental Healthcare during a Global Pandemic: Results from a Survey of Healthcare Professionals

Andrew Meyer, Otsuka Pharmaceuticals Inc

Mark Tancelosky, Andrew Meyer*, Fatima Sadat, Tara McKinley, Dana Pikul, Tarolyn Carlton, Reza Moghadam

W63. Longer Isn't Always Better: The Relationship between Phone Screening Interview Duration and MDD Clinical Trial Eligibility

Miriam Evans, Adams Clinical

Miriam Evans*, Jenicka Engler, Sarah Starling, Dennis Fagundo, Allison Aghjayan, Daniel Thorpe, Sarah Nicholas

W64. Studying the Impact of Patient Treatment Experiences on Patient Hope for Future Major Depressive Disorder Pharmacotherapies

Iresha Abeynayake, Axsome Therapeutics

Roger McIntyre, Greg Mattingly, Melissa Maravic, Kelly Birch, Pamela Romero Cruz, Dale Kappus, Herriot Tabuteau, Iresha Abeynayake*



= New Investigator Awardee



* = Pharmaceutical Pipeline Presentation

Thursday, June 2, 2022

12:30 p.m. - 2:00 p.m.

Poster Session II

Palomino Ballroom 4-10

T1. Gabapentin is an Effective Adjunct Medication for Benzodiazepine WithdrawalEdison Leung, University of Texas Health Science Center at Houston
McGovern Medical School

Edison Leung*, Daniel Ngo, Joe Espinoza, Lauren Beal, Catherine Chang, Gregory Cervenka, Dalsu Baris, Blake Lackey, Scott D. Lane, Hanjing Emily Wu

T2. AI-Based Adherence Predication for Patients: Leveraging a Mobile Application to Improve Clinical Trials

Michael Sand, Boehringer-Ingelheim Pharmaceutical Inc

Dooti Roy, Zheng Zhu, Lei Guan, Shaolei Feng, Kristen Daniels, Michael Sand*

T3. Transcranial Magnetic Stimulation for Methamphetamine Use Disorder and Potential Use During Pregnancy

Rana Jawish, University of Utah School of Medicine

Rana Jawish*, Daniel Pickrell, Keith Jones, Nathan Hoffman, Rebecca Jacobs, Tiffany Love, Brian Mickey

T4. Brain and Peripheral Distribution of Intranasal Radiolabeled PH94B in Laboratory Rats

Louis Monti, VistaGen Therapeutics, Inc.

Ross Baker, Mark A. Smith, Louis Monti*

T5. Negative Biases During the Processing of Faces Based on Emotion Expression in Major Depressive Disorder

Shani Waninger, Advanced Brain Monitoring

Shani Waninger*, Amir Meghdadi, Chris Berka

T6. Antidepressant Responses of Esketamine Nasal Spray and Atypical Antipsychotics in Pivotal Phase 3 Trials: A Meta-Analysis

Guang Chen, Janssen R & D, LLC

Lien Wang, Xiaowei Chen, Xiaojing Gu, Heidi De Smedt, Vanina Popova, Dong Jing Fu, Carla Canuso, Wayne Drevets, Guang Chen*



= New Investigator Awardee

✱ = Pharmaceutical Pipeline Presentation

- T7. Harnessing the Power of Scientific Surveillance in Centralized Monitoring**
Timothy Peters-Strickland, PPD Biotech Solutions
Timothy Peters-Strickland*, Andrew Hartley, Dorota Nieciecka, John Hamlet, Martin Brown, Rakhi Kilaru, Yudong Zhao, Randy Brown
- T8. Effects of Cariprazine on Reducing Symptoms of Hostility and Agitation in Patients with Manic or Mixed Episodes of Bipolar I Disorder**
Leslie Citrome, New York Medical College
Leslie Citrome*, Ken Kramer, Huy-Binh Nguyen
-  **T9. Modifiable Behavioral Targets Associated with Subsyndromal Symptoms of Depression in Bipolar Disorder**
Jennifer Nicoloro-SantaBarbara, Brigham and Women's Hospital, Harvard Medical School
Jennifer Nicoloro-SantaBarbara*, Megan Shanahan, Katherine E. Burdick
- T10. Long-Term Lumateperone Treatment in Bipolar Disorder: Six-Month Open-Label Extension Study**
Ian D'Souza, Intra-Cellular Therapies, Inc.
Mauricio Tohen, Suresh Durgam, Ian D'Souza*, Susan G. Kozauer, Richard Chen, Sharon Mates
- T11. Effect of Lumateperone (ITI-007) on Quality of Life and Functional Disability in the Treatment of Bipolar Depression**
John B. Edwards, Intra-Cellular Therapies, Inc.
Roger McIntyre, Suresh Durgam, John B. Edwards*, Ian D'Souza, Tobie Escher, Bradford Loo, Jason Huo, Richard Chen, Rakesh Jain
- T12. Safety and Tolerability of Brexpiprazole for the Treatment of Borderline Personality Disorder: A 12-Week, Flexible-Dose, Open-Label Extension Study**
Brian Rothman, Otsuka Pharmaceutical Development and Commercialization Inc.
Brian Rothman*, Claudette Brewer, Denise Chang, Mary Hobart, Nanco Hefting, Robert D. McQuade, Jon Grant
- T13. Still Working: Professional Subjects Before and During the Pandemic**
Thomas Shiovitz, CenExel CNR | CTSdatabase
Thomas Shiovitz*, Chelsea Steinmetz, Brittany Steinmiller



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

T14. Efficacy and Safety of BI 425809 in Patients with Schizophrenia: CONNEX, a Phase III Randomized Controlled Trial Program

Glen Wunderlich, Boehringer Ingelheim

Glen Wunderlich*, Zuzana Blahova, Sanjay Hake, Satoru Ikezawa, Stephen Marder, Peter Falkai, John Krystal

T15. Enhancing Participant Retention: Lessons Gained from Attention-Deficit/Hyperactivity and Anxiety Disorders Clinical Trial Methodologies

Elan Cohen, Hassman Research Institute

Elan Cohen*, Howard Hassman, David Walling, Vera Grindell, John Sonnenberg, Katarzyna Wyka, Brett English, Jaclyn Lobb, Djouher Hough, Cassie Blanchard, Larry Ereshefsky

T16. Ulotaront Improves Metabolic Parameters in Rodent Models of Weight Gain and Hyperglycemia

Courtney Zeni, Sunovion Pharmaceuticals

Nina Dedic, Phillip G. Jones, Serena Wu, Christopher Anacker, Eva Hajos-Korcsok, Colleen Synan, Snezana Milanovic, Courtney Zeni*, Seth C. Hopkins, Linda Bristow, Kenneth S. Koblan

T17. The Prediction of Suicidal Ideation as a Function of Daily Mood and Anxiety Scores Collected Using Mobile Health (mHealth) Technology in Patients Undergoing Treatment for Depression

Jayesh Kamath, University of Connecticut Health Center

Parit Patel, Grace Chan, Bing Wang, Jayesh Kamath*

T18. Zuranolone Safety and Efficacy in Postmenopausal Women with Major Depressive Disorder (MDD): Results from the Phase 3 Shoreline Study

Scott Aaronson, Sheppard Pratt

Scott Aaronson*, Gregory Mattingly, Robert Lasser, Indrani Nandy, Nilanjana Rana, Colville Brown, Richard Hughes, Divya Narayanan, James Doherty, Andrew Cutler

T19. The Safety, Efficacy, and Need for Additional Treatment Courses of Zuranolone 50 mg in the Open-label, Phase 3 SHORELINE Study of Patients with Major Depressive Disorder

Andrew Cutler, SUNY Upstate Medical University

Andrew Cutler*, Scott Aaronson, Gregory Mattingly, Robert Lasser, Indrani Nandy, Nilanjana Rana, Colville Brown, Catherine Miller, Fiona Forrestal, Mona Kotecha, James Doherty



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

- T20. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: Results of a Randomized Phase 3 Placebo-Controlled Study (Study 301)**
 Paul Yeung, AbbVie
 Gary S. Sachs, Paul Yeung*, Ludmyla Rekeda, Arifulla Khan, Julie L. Adams, Maurizio Fava
- T21. Safety and Tolerability of Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: A Pooled Analysis of Phase 2B and 3 Clinical Trials**
 Paul Yeung, AbbVie
 Michael E. Thase, Paul Yeung*, Arlene Hankinson, Meng Liu, Ludmyla Rekeda, Willie R. Earley
- T22. Impact of AXS-05, an Oral NMDA Receptor Antagonist, on Anhedonic Symptoms in Major Depressive Disorder**
 Amanda Jones, Axsome Therapeutics
 Amanda Jones*, Roger McIntyre, Caroline Streicher, Zachariah Thomas, Herriot Tabuteau
- T23. Decisions to Continue, Switch, or Discontinue Antidepressants Among Patients with Major Depressive Disorder: Outcomes from a Real-World, Evidence-Based Survey with a Focus on Sexual Dysfunction**
 Anita H. Clayton, University of Virginia
 Judith J. Stephenson, Maelys Touya, Debra F. Lawrence, Lambros Chrones, Chia-Chen Teng, Anita H. Clayton*
- T24. The Safety and Efficacy of COMP360 Psilocybin Therapy as Adjunctive Treatment in Treatment- Resistant Depression**
 Claudia Sisa, COMPASS Pathways Ltd.
 Guy Goodwin, Susan Stansfield, David Feifel, Veronica O’Keane, John R. Kelly, Claudia Sisa*, Sunil Mistry, Samuel Williams, Ekaterina Malievskaia
- T25. Sociodemographic Characteristics, Health-Related Behaviors, and Clinical Characteristics by Depression Diagnosis Status: A National Health and Wellness Survey Analysis**
 Jacqueline Pesa, Janssen Scientific Affairs, LLC
 Jacqueline Pesa*, Janelle Cambron-Mellott, Muideen Adigun, Nate Way, H. Jean Wright



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

T26. Factors Associated with Adherence to Esketamine Nasal Spray Among Major Depressive Disorder (MDD) Subpopulations: Role of Social Determinants and Distance from Treatment Centers

Jacqueline Pesa, Janssen Scientific Affairs, LLC

Joshua N. Liberman, Pinyao Rui, Kruti Joshi, Jacqueline Pesa*, Lisa Hardin

T27. Real-World Healthcare Resource Utilization and Costs of Patients with Major Depressive Disorder with Acute Suicidal Ideation or Behavior Initiating Esketamine in United States

Kruti Joshi, Janssen Scientific Affairs, LLC

Amanda Teeple, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Gabrielle Caron-Lapointe, Kruti Joshi*

T28. Access and Real-World Use of Esketamine Among Patients with Major Depressive Disorder with Acute Suicidal Ideation or Behavior Across Various Health Plans in United States

Kruti Joshi, Janssen Scientific Affairs, LLC

Amanda Teeple, Maryia Zhdanava, Dominic Pilon, Aditi Shah, Gabrielle Caron-Lapointe, Kruti Joshi*

T29. A Post Hoc Analysis of Patients Who Received Esketamine Nasal Spray Monotherapy in an Open-Label Safety Extension Study (SUSTAIN -3)

Dong Jing Fu, Janssen Research and Development, LLC

Dong Jing Fu*, Oliver Lopena, Phung Quach, Naim Zaki, Liping Sun



T30. The Impact of (2R,6R)-HNK and Reelin on iPSC-Derived Neurons from Treatment-Resistant Depression Patients

Jenessa Johnston, University of Victoria

Jenessa Johnston*, Brandi Quintanilla, Peixiong Yuan, Hector Caruncho, Mani Yavi, Bashkim Kadriu, Carlos Zarate

T31. Incidence of Abnormal Dreams and Nightmares in Insomnia Patients Treated with Lemborexant

Jocelyn Cheng, Eisai Inc.

Thomas Roth, Jane Yardley, Kate Pinner, Dinesh Kumar, Jocelyn Cheng*, Margaret Moline

T32. Assessment of Nocturnal Wake Bouts in Adults with Insomnia Treated with Lemborexant Versus Zolpidem

Margaret Moline, Eisai Inc.


Thomas Roth, Gary Zammit, Dinesh Kumar, Elizabeth Pappadopulos, Margaret Moline*



= New Investigator Awardee



* = Pharmaceutical Pipeline Presentation

- T33. Predictors of Pharmacotherapy Outcomes for Body Dysmorphic Disorder: A Machine Learning Approach**
Katharine Phillips, Weill Cornell Medical College/NewYork-Presbyterian Hospital
Katharine Phillips*, Joshua Curtiss, Emily Bernstein, Sabine Wilhelm
- T34. Phenomenology of Postpartum Psychosis: Preliminary Results from MGH Postpartum Psychosis Project**
Lee Cohen, Massachusetts General Hospital
Lee Cohen*, Rachel Vanderkruik, Miranda Arakelian, Taylor Church, Madison Dunk, Heather Harmon, Marlene Freeman
-  **T35. Attenuation of Oxycodone Seeking in Rats Without Effects on Motor or Cognitive Function with M5 Negative Allosteric Modulator VU6008667**
Laura Teal, Warren Center for Neuroscience Drug Discovery, Vanderbilt University
Laura Teal*, Edith Duncan, Michael Bubser, Craig Lindsley, Carrie Jones
- T36. Metabolic Parameters, Vital Signs, and Weight Change in Patients with Schizophrenia Switched to Treatment With Aripiprazole Lauroxil**
James McGrory, Alkermes, Inc.
Brian Miller, Sergey Yagoda, James McGrory*, Daniel J. Still, Steve Dingman, Meihua Wang
- T37. Characteristics and Treatment Patterns in Medicare Patients Newly Diagnosed with Schizophrenia with Traditional Fee-For Service Versus Private Medicare Advantage Insurance Coverage**
Dusica Hadzi Boskovic, Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC)
Christie Teigland, Seung Kim, Iman Mohammadi, Barnabie Agatep, Dusica Hadzi Boskovic*
- T38. A Single-Day, Two-Injection Start Regimen for Aripiprazole Once-Monthly in Patients with Schizophrenia or Bipolar I Disorder Who Are Not Being Treated with Oral Aripiprazole**
Pedro Such, H. Lundbeck A/S
Jessica Madera-McDonough, Pedro Such*, Matt Harlin, Frank Larsen, Murat Yildirim



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

T39. Effect of Paliperidone Palmitate Versus Oral Antipsychotics on Treatment Failure in Adults with Recent-Onset Schizophreniform Disorder: An Analysis of the DREaM Study

Karen Johnston, Janssen Scientific Affairs, LLC

Karen Johnston*, Ibrahim Turkoz, Larry Alphs, Oliver Lopena, H. Lynn Starr

T40. Clinical Rationale and Design of the ARISE Study: A Phase 3 Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adjunctive KarXT in Patients with Inadequately Controlled Schizophrenia

Ronald Marcus, Karuna Therapeutics

Ronald Marcus*, Andreas Olofsson, Megan Leader



T41. Semaglutide for the Treatment of Weight Gain Associated with Antipsychotics in Patients with Schizophrenia: Proposed Design for a Randomized Controlled Trial

Moein Foroughi, SUNY Downstate Medical Center

Moein Foroughi*, Rishab Gupta, Nina Schooler

T42. Impact of Timing of Initiation of Aripiprazole 400mg Long-Acting Injectable on Healthcare Resource Use and Cost in Patients with Schizophrenia

Heidi Waters, Otsuka Pharmaceutical Development and Commercialization, Inc. (OPDC)

Leslie Citrome, Robert Stellhorn, Heidi Waters*, Maelys Touya, Maxine Chen, Sandipan Bhattacharjee, Christine Farkas

T43. Utility and Usability of Aripiprazole Tablets with Sensor: Aggregated Survey Data from 3 Clinical Trials of Participants with Serious Mental Illness

Tarolyn Carlton, Otsuka Pharmaceutical Development and Commercialization, Inc.

Tarolyn Carlton*, Chip Meyer, Jeffrey M. Cochran, J. Corey Reuteman-Fowler



T44. Biological Embeddings of Early Trauma: The Role of Increased Prefrontal Glutamatergic Synaptic Strength

Amanda Tamman, Baylor College of Medicine

Amanda Tamman*, Sanjay J. Mathew, Chadi Abdallah



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

- * T45. COMP360 Psilocybin Therapy in Treatment-Resistant Depression: Results of a Large Randomized Controlled Phase I/II Monotherapy Study and an Exploratory Uncontrolled Adjunctive Therapy Study**
 Joyce Tsai, COMPASS Pathways Ltd.
 Joyce Tsai*, Guy Goodwin, Lindsey Marwood, Sunil Mistry, Claudia Sisa, Susan Stansfield, Sam Williams, Ekaterina Malievskaia
- * T46. Emerging Profile of TAAR1 Agonist Ulotaront: Preclinical and Clinical Evidence for an Emerging Pharmacological Class**
 Seth C. Hopkins, Sunovion Pharmaceuticals, Inc.
 Seth C. Hopkins*
- T47. Safety and Tolerability Profile of Zuranolone From the LANDSCAPE (Major Depressive Disorder) and NEST (Postpartum Depression) Clinical Development Programs**
 Kristina Deligiannidis, Zucker Hillside Hospital
 Kristina Deligiannidis*, Anita H. Clayton, Robert Lasser, Colville Brown, Richard Hughes, Nilanjana Rana, Mona Kotecha, James Doherty
- T48. Adjunctive Use of Troriluzole, a Novel Glutamate Modulator, in Patients with Obsessive Compulsive Disorder: Impact of Baseline Disease Severity on Treatment Outcomes**
 Azim Munivar, Biohaven Pharmaceuticals
 Loren Aguiar, Azim Munivar*, Alexander Bystritsky, Christopher Pittenger
- * T49. Brainsonix Technology of Low Intensity Focused Ultrasound Pulse (LIFUP) for Targeted Transcranial Neuromodulation and Delivery of Biological Substances in the Brain**
 Alexander Bystritsky, UCLA Semel Institute for Neuroscience and Human Behavior
 Alexander Bystritsky*, Sheldon Jordan
- T50. Healthcare Cost Savings Through Improved Bipolar I Disorder Identification Using the Rapid Mood Screener (RMS) in Patients with Major Depressive Disorder**
 Amanda Harrington, AbbVie
 Roger McIntyre, Lisa Bloudek, Jack Timmons, Patrick Gillard, Amanda Harrington*



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

- T51. A Novel Prediction Model for the Early Identification of Misdiagnosed Bipolar I Disorder Among Patients with Major Depressive Disorder**
Amanda Harrington, AbbVie
Roger McIntyre, François Laliberté, Guillaume Germain, Annalise Hilts, Amanda Harrington*
- T52. Effect of Lurasidone on Depressive Symptoms, Function, and Quality of Life Outcomes; A Post-Hoc Multiple Responder Analysis**
Michael Tocco, Sunovion Pharmaceuticals, Inc.
Michael Tocco*, Yongcai Mao, Andrei Pikalov
- T53. Daily and Social Functioning in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil**
James McGrory, Alkermes, Inc.
Sabina Gasper, Steve Dingman, Meihua Wang, Brittany Roy, James McGrory*
- T54. PRAX-114, an Extrasynaptic-Preferring GABA-A Receptor Positive Allosteric Modulator: A Phase 2 Trial Evaluating Multiple Dose Safety, Tolerability, and Preliminary Efficacy in Major Depressive Disorder**
Nicholas DeMartinis, Praxis Precision Medicines, Inc.
Nicholas DeMartinis*, Shane Raines, Marion Wittman, Bernard Ravina
- T55. Genetic Moderators of Cognitive and Functional Imaging Predictors of Employment Status in People with Schizophrenia**
Rachael Blackman, Clinical and Translational Neuroscience Branch, National Institute of Mental Health
Rachael Blackman*, Daniel Eisenberg, Dwight Dickinson, Michael Gregory, Karen Berman
- T56. How Decentralized Clinical Trials Deliver on Diversity: Case Studies**
Christopher Reist, Science 37
Christopher Reist*, Jason Bain, Vincent Ingram, Jessica Walker, Rachel Lind
- T57. A Pilot Study of Low-Intensity Focused Ultrasound for Treatment-Resistant Obsessive-Compulsive Disorder**
Kaya Jordan, The Regeneration Project
Kaya Jordan*, Kennedy Mahdavi, Jonathan Haroon, Elisabeth Rindner, Margaret Zielinski, Barshen Habelhah, Sergio Becerra, Alexander Bystritsky, Taylor Kuhn, Sheldon Jordan



= New Investigator Awardee

* = Pharmaceutical Pipeline Presentation

T58. Methylone, a Rapid Acting Entactogen with Robust Antidepressant-Like Activity in the Forced Swim Test

Jennifer Warner-Schmidt, Transcend Therapeutics

Jennifer Warner-Schmidt*, Christopher Pittenger, Martin Stogniew, Blake Mandell, Sarah J. Olmstead, Benjamin Kelmendi

T59. Risk of Mortality Associated with Pimavanserin Compared with Atypical Antipsychotics in Patients with Parkinson's Disease-Related Psychosis

J. Bradley Layton, RTI Health Solutions

J. Bradley Layton*, Lisa McQuay, Joan Forns, Heather E. Danysh, Colleen Dempsey, Mary S. Anthony, Mary Ellen Turner

T60. ANC-501: A Novel V1b Receptor Antagonist for Major Depressive Disorder

Stephen Kanes, Ancora Bio

Stephen Kanes*, Lara Dennie

T61. A Case Study of Low-Intensity Focused Ultrasound for Treatment-Resistant Generalized Anxiety Disorder and Major Depressive Disorder

Elisabeth Rindner, The Regenesys Project

Elisabeth Rindner*, Margaret Zielinski, Jonathan Haroon, Kaya Jordan, Kennedy Mahdavi, Barshen Habelhah, Sergio Becerra, Alexander Bystritsky, Taylor Kuhn, Sheldon Jordan

T62. Anger Attacks among Clinical Trial Participants with Major Depressive Disorder

Miriam Evans, Adams Clinical

Miriam Evans*, Jenick Engler, Grace Koo, Daniel Thorpe, Sarah Nicholas, Dyanna Domilici

T63. Naturalistic Clinical Evidence for the Use of Methylone in the Treatment of PTSD: A Case Series

Benjamin Kelmendi, Transcend Therapeutics; Yale School of Medicine, US Department of Veteran Affairs, National Center for PTSD

Benjamin Kelmendi*, Christopher Pittenger, Terence Ching, Magi Farre, Blake Mandell, Martin Stogniew, Mark Seelig, Lynnette Averill



= New Investigator Awardee



= Pharmaceutical Pipeline Presentation

[illegible]

Aaronson, Scott	23, 25, 44, 57, 78, 79, 83, 88	Borkar, Durga	72
Abdallah, Chadi	92	Boskovic, Dusica Hadzi	80, 81, 91
Abeynayake, Iresha	85	Brady, Chris	77
Acharya, Nimish	82	Brewer, Claudette	76, 87
Adams, Julie	78, 89	Bristow, Linda	88
Adigun, Muideen	78, 89	Brown, Colville	77, 78, 83, 88, 93
Agarwal, Mahavir	43, 51, 74	Brown, Martin	87
Agatep, Barnabie	80, 91	Brown, Randy	87
Aghjayan, Allison	85	Bubser, Michael	91
Aguiar, Loren	93	Bullock, Amy	83
Ahmed, Mohammed	23	Burdick, Katherine	54, 87
Aislaitner, Georgios	10, 52	Bystritsky, Alexander	43, 85, 93, 94, 95
Akerman, Sarah C.	81	Cabrera, Patricia	79
Alataris, Konstantinos	80	Calkin, Cynthia	74
Alkhatib, Rifqi	85	Cambron-Mellott, Janelle	78, 89
Alphs, Larry	92	Canuso, Carla	56, 86
Alva, Gustavo	83	Carey, Theadia L.	23
Anacker, Christopher	88	Carlton, Tarolyn	85, 92
Anand, Amit	23, 65	Caron-Lapointe, Gabrielle	90
Andreazza, Ana	76	Caruncho, Hector	90
Anthony, Mary S.	95	Castelli, Mariacristina	75
Arakelian, Miranda	91	Cervenka, Gregory	86
Asgharnejad, Mahnaz	83	Chan, Grace	88
Averill, Lynnette	95	Chang, Catherine	86
Bahekar, Pratik	23	Chang, Denise	76, 87
Bain, Jason	94	Chang, Ih	83
Baker, Justin	66	Chang, Marisa	85
Baker, Ross	22, 56, 86	Chen, Chi-Chang	81
Balakrishnan, Kanan	75	Chen, Guang	86
Ballard, Elizabeth	41	Chen, Maxine	76, 82, 92
Baris, Dalsu	86	Chen, Richard	87
Barrows, Hannah	85	Chen, Xiaotian	78
Beach, Scott	12, 62	Chen, Xiaowei	86
Beal, Lauren	86	Cheng, Jocelyn	80, 90
Becerra, Sergio	75, 85, 94, 95	Chiapperino, Dominic	9, 52
Berka, Chris	86	Ching, Terence	95
Berman, Karen	94	Christensen, Michael Cronquist	78
Bernstein, Emily	91	Chrones, Lambros	89
Bhattacharjee, Sandipan	92	Church, Taylor	91
Biernacka, Joanna	75, 76	Citrome, Leslie	25, 43, 51, 62, 87, 92
Bierut, Laura	75	Clark, Crystal	43
Birch, Kelly	85	Claxton, Amy	81
Blackman, Rachael	94	Clayton, Anita H.	40, 77, 89, 93
Blahova, Zuzana	88	Cochran, Jeffrey M.	92
Blanchard, Cassie	88	Cohen, Elan	88
Bloudek, Lisa	93		
Bookheimer, Susan	75		

Cohen, Lawrence	23, 46	Durgam, Suresh	76, 87
Cohen, Lee	21, 22, 83, 91	Duvvuri, Sridhar	83
Colasurdo, Elizabeth	76	Dwyer, Jennifer	38
Coombes, Brandon	75, 76	Earley, Willie R.	77, 89
Coppola, Diana	80	Edwards, John B.	87
Correll, Christoph	24, 25, 74, 76	Egan, Michael	44, 84
Crismon, Lynn	23	Eisenberg, Daniel	94
Cruz, Pamela Romero	85	Engler, Jenicka	80, 85, 95
Cuellar-Barboza, Alfredo	75, 76	English, Brett	38, 88
Culpepper, Larry	23	Epperson, Cynthia	66
Curtiss, Joshua	91	Ereshefsky, Larry	38, 88
Cusin, Cristina	23, 47	Escher, Tobie	87
Cutler, Andrew	77, 78, 83, 88	Espinoza, Joe	86
Cvijanovic, Luka	75	Espinoza, Randall	54
Dakwar, Elias	55	Etropolis, Mila	79
Dandurand, Ann	83	Evans, Miriam	80, 85, 95
Dang, Bianca	75	Evans, Rebecca	83
Daniels, Kristen	86	Fagundo, Dennis	80, 85
Danysh, Heather E.	95	Falkai, Peter	88
Darcy, Alison	66	Falk, Daniel	22
Davis, John	39	Faraone, Stephen V.	75
Davis, Lori	22, 24	Farchione, Tiffany	8, 19, 22, 24, 33, 52, 72, 73
Davis, Michael	24, 33, 56	Farkas, Christine	92
Davis, Robert E.	76	Farre, Magi	95
Debattista, Charles	83	Fatt, Cherise Chin	42
de Carvalho Lima, Camila Nayane	7, 48	Fava, Maurizio	23, 40, 65, 77, 89
Dedic, Nina	88	Feifel, David	78, 79, 89
Deligiannidis, Kristina	43, 80, 93	Felder, Christian C.	82
Delphin-Rittmon, Miriam E.	16, 63	Feng, Shaolei	86
DeMartinis, Nicholas	83, 94	Fernandez, Fabian-Xosé	82
Dempsey, Colleen	95	Fischer, Bernard	19, 73
Dennie, Lara	95	Fitzgerald, Heather	76, 82
Dickinson, Dwight	94	Flanders, William Dana	81
Dingman, Steve	91, 94	Forns, Joan	95
Dirks, Bryan	22	Foroughi, Moein	7, 92
Dobbins, Thomas	77	Forrestal, Fiona	77, 78, 83, 88
Doherty, James	77, 78, 83, 88, 93	Frank, Ellen	66
Domilici, Dyanna	80, 95	Fratantonio, James	81
Dong, Cheng	83	Freeman, Marlene	22, 25, 83, 91
Doshi, Dilesh	85	Freudenreich, Oliver	18, 63
Drevets, Wayne	79, 86	Frye, Mark	54, 74, 75, 76
Drgonova, Jana	17, 63	Fu, Dong Jing	86, 90
D'Souza, Ian	87	Fu, Eric	77
Dunayevich, Eduardo	83	Fukuda, Andrew	7, 46
Duncan, Edith	91	Gadad, Bharathi	23
Dunk, Madison	91	Gailledreau, Béatrice	80
Dunlop, Boadie W.	78, 79		

Gailledreau, Joël	80	Hankinson, Arlene	89
Galderisi, Silvana	83	Hanson, Elizabeth	83
Garcia, Manny	83	Harber, Steven	80
Gaspar, Sabina	81, 94	Hardin, Lisa	90
Gaynes, Bradley	23	Harkavy-Friedman, Jill	67
Ge, Tingting	83	Harlin, Matt	82, 91
Germain, Guillaume	84, 94	Harmon, Heather	91
Gilbert, Jessica	73	Haroon, Ebrahim	23
Gillard, Patrick	93	Haroon, Jonathan	85, 94, 95
Gitlin, Michael	54	Harrington, Amanda	78, 84, 93, 94
Giugliano, Amy	83	Hartley, Andrew	87
Glick, Ira	39, 77	Harvey, Philip	48, 77
Gliske, Kate	75	Hassman, Howard	88
Goff, Donald	39	He, Jing	81
Goldberg, Joseph F.	25	Hefting, Nanco	76, 87
Goldstein, Evan	7, 47	Hellerstein, David	78, 79
Goldwasser, Eric	7, 82	Hendrickson, Rebecca	84
Goodwin, Guy	78, 79, 89, 93	Henry, Michael	23
Gopinath, Srinath	23	Herman, Alexander	7
Gordon, Josh	13, 62	Higa, Sara	84
Gorritz, Magdaliz	81	Hiller, Sonja	75
Grabb, Margaret	38	Hilts, Annalise	94
Grace, Koo	80	Ho, Ming-Fen	75
Grandner, Michael	82	Hoare, Sam R. J.	81
Grant, Jon	76, 87	Hobart, Mary	76, 87
Gregory, Michael	94	Hobson, Scott	38
Grigoriadis, Dimitri E.	81	Hoffman, Nathan	86
Grindell, Vera	88	Holiday, Christopher	79
Grob, Charles	52	Homitsky, Sarah	80
Gross, Hyman	85	Hong, Elliot	82
Grucza, Richard	75	Hopkins, Seth C.	43, 82, 88, 93
Gu, Xiaojing	86	Hough, Djouher	88
Guan, Lei	86	Hu, Yuliang	81
Gupta, Rishab	92	Hughes, Richard	83, 88, 93
Gupta, Vikas	23	Huo, Jason	76, 87
Gur, Raquel	38	Ibroci, Erona	80
Gurrell, Rachel	44, 83	Ikezawa, Satoru	88
Habelhah, Barshen	85, 94, 95	Ingram, Vincent	94
Haberkamp, Marion	20, 73	Iosifescu, Dan	23, 25
Hahn, Margaret	74	Iyer, Srividya	81
Hajos-Korcsok, Eva	88	Jacobs, Gabriel	83
Hake, Sanjay	88	Jacobs, Rebecca	86
Halavi, Sabrina	75	Jacob, Sunu	80
Hall, Nancy	80	Jain, Rakesh	84, 87
Hameed, Ahmad	23	Jawish, Rana	86
Hameed, Usman	23	Jezzini, Sofia	75
Hamlet, John	87	Jha, Manish	37, 41, 58
Han, Xue	82	Johnston, Jenessa	7, 90

Johnston, Karen	92	Ku, Benson	7, 46
Jones, Amanda	84, 89	Kudwa, Andrea	81
Jones, Carrie	91	Kuhn, Taylor	75, 85, 94, 95
Jones, Keith	86	Kumar, Dinesh	80, 90
Jones, Phillip G.	88	Kumar, Rakesh	7, 45
Joobar, Ridha	81	Kumar, Shikhar	85
Jordan, Ayana	23	Kung, Simon	56, 81
Jordan, Kaya	85, 94, 95	Kupfer, David J.	22
Jordan, Sheldon	85, 93, 94, 95	LaCivita, Cynthia	9, 52
Joseph, Boney	75	Lackey, Blake	86
Joshi, Kruti	41, 79, 90	Laliberté, François	84, 94
Jung, JungAh	83	Lally, Cathy	81
Kablinger, Anita	77	Lane, Scott D.	86
Kaddurah-Daouk, Rima	74	Langenecker, Scott	67
Kadriu, Bashkim	90	Larsen, Frank	82, 91
Kamath, Jayesh	88	Lasser, Robert	77, 78, 83, 88, 93
Kane, John	25, 48	Lavretsky, Helen	71
Kanes, Stephen	95	Lawrence, Debra F.	89
Kappus, Dale	85	Layton, J. Bradley	95
Karkare, Swapna	79	Leader, Megan	92
Karp, Jordan	71, 82	Lennie, Janelle	75
Karpyak, Victor	75	Lenze, Eric	12, 62, 65, 71
Kavanagh, Eileen	58	Leonard, Kaitlin	79
Kelly, John R.	89	Lepage, Martin	81
Kelmendi, Benjamin	95	Leung, Edison	86
Kerolous, Majid	77, 78	Liang, Katharine	7, 76
Kesari, Santosh	85	Liberman, Joshua N.	90
Khan, Arifulla	89	Li, Ge	76
Kilaru, Rakhi	87	Li, Hu	75
Kim, Seung	80, 91	Li, Jianheng	81
King, Bridget	80	Lin, Yezhe	77
Kinon, Bruce	24, 33	Lindenmayer, Jean-Pierre	39
Koblan, Kenneth	82, 88	Lind, Rachel	94
Kobylski, Lauren	83	Lindsley, Craig	91
Kollins, Scott	72	Liu, Meng	89
Komaroff, Marina	75	Lobb, Jaclyn	88
Koo, Grace	95	Loo, Bradford	87
Koob, George	14, 62	Lopena, Oliver	90, 92
Kornstein, Susan G.	21, 23, 25	Lorch, Daniel	80
Kotecha, Mona	77, 78, 83, 88, 93	Lord, Benjamin	79
Kozauer, Susan G.	76, 87	Love, Tiffany	86
Kozicz, Tamas	76	Lowenthal, Catherine	58
Kramer, Ken	78, 87	Macaluso, Matthew	25
Kramer, Luke	53	MacKnight, Sean	84
Kraus, John	53	Madera-McDonough, Jessica	76, 82, 91
Krystal, Andrew	17, 63	Mago, Rajnish	23
Krystal, John	88	Mahdavi, Kennedy	85, 94, 95

Mahendran, Malena	84	Montelongo, Mario	47
Malhotra, Manoj	80	Monti, Louis	86
Malhotra, Shishuka	64	Monti, Martin	75
Malievskaia, Ekaterina	78, 79, 89, 93	Montoya, Ivan	15, 62
Malla, Ashok	81	Montoya, Iván	22, 24, 33
Mandell, Blake	95	Moon, Irene	75
Mantua, Valentina	22	Moore, Grace	80
Mao, Yongcai	84, 94	Moreno, Francisco	22, 24, 25, 53
Maravic, Melissa	85	Munivar, Azim	93
Marcus, Ronald	92	Murphy, Nicholas	7, 48, 73
Marder, Stephen	22, 25, 39, 88	Murrough, James	38
Mariano, Timothy	66	Murthy, Venkatesha	83
Marshall, Wyatt	82	Mustafa, Sally	81
Martin, Rachel	77	Nagele, Robert	82
Marwood, Lindsey	78, 79, 93	Nandy, Indrani	77, 78, 83, 88
Masand, Prakash	78	Narayanan, Divya	77, 83, 88
Mates, Sharon	76, 87	Nations, Kari	56
Mathew, Sanjay	23, 25, 37, 41, 55, 73, 83, 92	Nava, Francisco Romo-	76
Mattingly, Gregory	78, 83, 85, 88	Nemeroff, Charles	24
McDonald, Sean	77	Newcomer, John	22
McDonough, Jessica	76	Ng, Michelle	82
McElroy, Susan	76	Ngo, Daniel	86
McGrory, James	81, 91, 94	Ngo, Quyen	75
McIntyre, Roger	78, 84, 85, 87, 89, 93, 94	Nguyen, Huy-Binh	78, 87
McKinley, Tara	85	Nia, Anahita Bassir	23
McQuade, Robert D.	76, 87	Nicholas, Sarah	80, 85, 95
McQuay, Lisa	95	Nichter, Brandon	6, 52
Meeves, Suzanne	75	Nicoloro, Jennifer	7, 87
Meghdadi, Amir	86	Nieciecka, Dorota	87
Merikle, Elizabeth	77	Nielson, Elizabeth	57
Meyer, Andrew	85	Nierenberg, Andrew	24
Meyer, Chip	92	Nock, Matthew	67
Mickey, Brian	24, 48, 86	Nunes, Edward	51
Milanovic, Snezana	82, 88	Nunez, Nicolas	54, 75, 76
Miller, Brian	91	O'Connor, Ed	85
Miller, Catherine	78, 88	Oesterle, Tyler	75
Miller, Tammy	57	Ogirala, Ajay	82
Milsom, Vanessa	79	O'Keane, Veronica	89
Mintz, Carrie	75	Olmstead, Sarah J.	95
Mistry, Sunil	78, 79, 89, 93	Olofsson, Andreas	92
Mitsi, Georgia	66	Opler, Mark G. A.	81
Moghadam, Reza	85	O'Quinn, Stephen	45, 77
Mohammadi, Iman	80, 91	Osborne, Lauren	40
Moline, Margaret	80, 90	Ozerdem, Aysegul	76
Mondick, John T.	75	Palmer, Emily	85
Montano, C. Brendan	80	Pandina, Gahan	79
		Pani, Luca	22, 72
		Papakostas, George	25, 40, 41, 65

Pappadopulos, Elizabeth	90	Ravina, Bernard	94
Parikh, Mousam	84	Reist, Christopher	94
Parikh, Sagar	74, 83	Rekeda, Ludmyla	77, 78, 89
Park, Minkyung	24	Renger, John	83
Pastino, Gina	83	Renteria, Miguel E.	82, 85
Patel, Kiren	78	Resendez, Manuel Gardea	7, 75, 76
Patel, Parit	88	Reuteman-Fowler, J. Corey	92
Patel, Rashmi	85	Reynolds III, Charles F.	5, 52, 71
Payne, Jennifer	40	Riesenberg, Robert	77
Pederson, Aderonke Bamgbose	7	Rindner, Elisabeth	85, 94, 95
Perdomo, Carlos	80	Riva-Posse, Patricia	55
Pereles, Scott	85	Robakis, Thalia	80
Perlis, Michael	82	Robinson, Sophia	84
Perlis, Roy	11, 61	Rogers, James A.	82
Perry, Benjamin	74	Ross, David	58
Pesa, Jacqueline	78, 89, 90	Rothman, Brian	76, 87
Peskind, Elaine	76	Roth, Thomas	90
Peters-Strickland, Timothy	87	Roy, Brittany	81, 94
Pham, Theresa	83	Roy, Dooti	86
Philips, Lionel	53	Rui, Pinyao	90
Phillips, Katharine	24, 25, 33, 91	Ruiz-White, Inez	53
Pickrell, Daniel	86	Rush, A. John	82
Pikalov, Andrei	84, 94	Sabban, Esther	41
Pikul, Dana	85	Sachez, Raymond	83
Pilon, Dominic	79, 90	Sachs, Gary S.	77, 89
Pinner, Kate	90	Sadat, Fatima	85
Pittenger, Christopher	93, 95	Sanacora, Gerard	55
Pollack, Mark	24	Sand, Michael	86
Popova, Vanina	86	Sarampote, Christopher	21, 33
Potter, William	38	Sarkar, Joydeep	82
Pour, Koshar Safai	83	Saunders, Erika	21, 22, 56, 63
Presnall, Ned	75	Schatzberg, Alan	37
Price, Rebecca	55	Schley, Sara	42
Prieto, Miguel	76	Schmidt, Kristen	75
Quach, Phung	90	Schmidt, Simon Nitschky	78
Quicquaro, Alyssa	80	Schofer, Jane	76
Quintanilla, Brandi	90	Schooler, Nina	24, 33, 92
Radhakrishnan, Rajiv	24	Sebree, Terri	77
Raines, Shane	80, 94	Seelig, Mark	95
Rajagopalan, Krithika	85	Sen, Shuvayu	72
Ramaekers, Jan	44	Seppala, Marvin	75
Ramakrishnan, Nithya	6	Shah, Aditi	79, 90
Ramsawh, Holly	14, 62	Shah, Dhara	80
Rana, Nilanjana	78, 83, 88, 93	Shah, Jai	81
Rapaport, Mark	21, 33, 57, 61	Shanahan, Megan	87
Rashid, Nazia	85	Shi, Zhenhao	7, 46
Rasmusson, Ann	40	Shiovitz, Thomas	87
Ratti, Emiliangelo	83	Singh, Balwinder	55, 74, 75, 76

Singh, Jaskaran	44, 83	Thadani, Simran	82, 85
Sisa, Claudia	89, 93	Thase, Michael E.	18, 64, 65, 79, 89
Siskind, Dan	74	Thomas, Zachariah	84, 89
Skillon, Cedric	75	Thorpe, Daniel	80, 85, 95
Skime, Michelle	75	Tich, Nancy	77
Smedt, Heidi De	86	Timmons, Jack	93
Smith, Mark A.	86	Tocco, Michael	84, 94
Soares, Jair	24, 45	Tohen, Mauricio	87
Somers, Metten	78, 79	Tome, Maria	8, 19, 52, 73
Sonnenberg, John	88	Touya, Maelys	82, 89, 92
Spivak, Norman	7, 75	Trivedi, Madhukar	22, 24, 25, 37, 52, 67
Stansfield, Susan	78, 79, 89, 93	Truong, Thanh Thuy	7
Starling, Brittney	75	Tsai, Joyce	44, 51, 78, 79, 93
Starling, Sarah	80, 85	Tubbs, Andrew	7, 82
Starr, H. Lynn	92	Turkoz, Ibrahim	37, 92
Steinmetz, Chelsea	87	Turner, Mary Ellen	95
Steinmiller, Brittany	87	Tye, Sussanah	76
Stellhorn, Robert	92	Ulbricht, Christine	24
Stellman, Gabriel	82	Vanderkruik, Rachel	91
Stephenson, Judith J.	89	Vande Voort, Jennifer	55
Still, Daniel J.	91	Veldic, Marin	76
Stogniew, Martin	95	Versavel, Stacey	64, 83
Streicher, Caroline	84, 89	Viguera, Adele	83
Such, Pedro	76, 82, 91	Voineskos, Daphne	73
Sullivan, Maria A.	81	Wajs, Ewa	79
Sun, Ching-Fang	77	Walker, Jessica	94
Sun, Liping	90	Walling, David	88
Suppes, Trisha	25, 42, 43, 51, 57, 73	Wang, Bing	88
Surendran, Subina	82	Wang, Lien	86
Suthana, Nanthia	75	Wang, Lu	85
Suzuki, Katsumi	75	Wang, Meihua	81, 91, 94
Swanson, Randel	82	Waninger, Shani	86
Swartz, Holly	24, 25, 33, 42	Warner-Schmidt, Jennifer	95
Swenson, Andrew	75	Waters, Heidi	82, 92
Synan, Colleen	88	Way, Nate	78, 89
Szabo, Steven T.	82	Wee, Soon Nan	82, 85
Szpunar, Mercedes	40, 47, 83	Weiden, Peter	82
Tabuteau, Herriot	84, 85, 89	Weinshilboun, Richard	75
Tacelosky, Mark	85	Wenten, Made	81
Tamman, Amanda	7, 46, 92	White, Justin	77
Tcheremissine, Oleg	24	Whitney, Mike	85
Teal, Laura	91	Wijenaike-Bogle, Milli	84
Teepie, Amanda	90	Wilcox, Charles	64
Teigland, Christie	80, 91	Wilhelm, Sabine	91
Telch, Michael	41	Wilkinson, Samuel	55
Teng, Chia-Chen	89		
Terry-Lorenzo, Ryan	81		

Williams, Samuel	78, 79, 89, 93	Youssef, Nagy	45
Wilson, Sean D.	82	Yuan, Peixiong	90
Wise, Alexandria	64	Yuen, Alexa	82
Wittman, Marion	94	Zaki, Naim	90
Won, Yida	85	Zammit, Gary	90
Wright, H. Jean	78, 89	Zandi, Hasiba	80
Wu, Hanjing Emily	86	Zarate, Carlos	24, 43, 73, 90
Wu, Serena	88	Zeni, Courtney	88
Wunderlich, Glen	77, 88	Zhang, Alexander	77
Wyka, Katarzyna	88	Zhang, Cheng	75
Xu, Haiyan	79	Zhang, Yun	79
Xu, Kevin	7, 75	Zhao, Yudong	87
Yagoda, Sergey	81, 91	Zhdanava, Maryia	79, 90
Yardley, Jane	90	Zhu, Hongjian	78
Yasuda, Marie	81	Zhu, Zheng	86
Yavi, Mani	90	Zielinski, Margaret	85, 94, 95
Yeung, Paul	77, 78, 89	Zimmerman, Mark	24, 42
Yildirim, Murat	76, 82, 91	Zisook, Sidney	78, 79
Yohn, Samantha E.	82	Zuiker, Rob	83
Young, Allan H.	78, 79	Zuschlag, Zachary	79

SAVE THE DATE



2023 ASCP Annual Meeting **May 30–June 02, 2023** **Loews Miami Beach, Miami Beach, Florida**



ASCP

AMERICAN SOCIETY OF
CLINICAL PSYCHOPHARMACOLOGY

www.ascpp.org

ASCP Executive Office
5034A Thoroughbred Lane
Brentwood, Tennessee 37027

phone: 615-649-3085
fax: 888-417-3311
email: info@ascpp.org

